<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">43996</article-id><article-id pub-id-type="doi">10.7554/eLife.43996</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Stem Cells and Regenerative Medicine</subject></subj-group></article-categories><title-group><article-title>Homeostatic and tumourigenic activity of SOX2+ pituitary stem cells is controlled by the LATS/YAP/TAZ cascade</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-126798"><name><surname>Lodge</surname><given-names>Emily J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0932-8515</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-126800"><name><surname>Santambrogio</surname><given-names>Alice</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-126799"><name><surname>Russell</surname><given-names>John P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-126801"><name><surname>Xekouki</surname><given-names>Paraskevi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-119643"><name><surname>Jacques</surname><given-names>Thomas S</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-13329"><name><surname>Johnson</surname><given-names>Randy L</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-126802"><name><surname>Thavaraj</surname><given-names>Selvam</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-126803"><name><surname>Bornstein</surname><given-names>Stefan R</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-28038"><name><surname>Andoniadou</surname><given-names>Cynthia Lilian</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4311-5855</contrib-id><email>cynthia.andoniadou@kcl.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Centre for Craniofacial and Regenerative Biology, Faculty of Dentistry, Oral &amp; Craniofacial Sciences</institution><institution>King’s College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Division of Diabetes &amp; Nutritional Sciences, Faculty of Life Sciences &amp; Medicine</institution><institution>King's College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Department of Medicine III</institution><institution>University Hospital Carl Gustav Carus, Technische Universität Dresden</institution><addr-line><named-content content-type="city">Dresden</named-content></addr-line><country>Germany</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Endocrinology</institution><institution>King's College Hospital NHS Foundation Trust</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff5"><label>5</label><institution>UCL GOS Institute of Child Health and Great Ormond Street Hospital for Children NHS Foundation Trust</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">Department of Cancer Biology</institution><institution>The University of Texas, MD Anderson Cancer Center</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution content-type="dept">Centre for Oral, Clinical and Translational Sciences, Faculty of Dentistry, Oral &amp; Craniofacial Sciences</institution><institution>King's College London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Horsley</surname><given-names>Valerie</given-names></name><role>Reviewing Editor</role><aff><institution>Yale University</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Bronner</surname><given-names>Marianne E</given-names></name><role>Senior Editor</role><aff><institution>California Institute of Technology</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>26</day><month>03</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>8</volume><elocation-id>e43996</elocation-id><history><date date-type="received" iso-8601-date="2018-11-28"><day>28</day><month>11</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2019-03-25"><day>25</day><month>03</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Lodge et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Lodge et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-43996-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.43996.001</object-id><p>SOX2 positive pituitary stem cells (PSCs) are specified embryonically and persist throughout life, giving rise to all pituitary endocrine lineages. We have previously shown the activation of the STK/LATS/YAP/TAZ signalling cascade in the developing and postnatal mammalian pituitary. Here, we investigate the function of this pathway during pituitary development and in the regulation of the SOX2 cell compartment. Through loss- and gain-of-function genetic approaches, we reveal that restricting YAP/TAZ activation during development is essential for normal organ size and specification from SOX2+ PSCs. Postnatal deletion of LATS kinases and subsequent upregulation of YAP/TAZ leads to uncontrolled clonal expansion of the SOX2+ PSCs and disruption of their differentiation, causing the formation of non-secreting, aggressive pituitary tumours. In contrast, sustained expression of YAP alone results in expansion of SOX2+ PSCs capable of differentiation and devoid of tumourigenic potential. Our findings identify the LATS/YAP/TAZ signalling cascade as an essential component of PSC regulation in normal pituitary physiology and tumourigenesis.</p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.43996.002</object-id><title>eLife digest</title><p>The pituitary is a gland inside the head that releases hormones that control major processes in the body including growth, fertility and stress. Diseases of the pituitary gland can prevent the body from producing the appropriate amounts of hormones, and also include tumours.</p><p>A population of stem cells in the pituitary known as SOX2 cells divide to make the specialist cells that produce the hormones. This population forms as the pituitary develops in the embryo and continues to contribute new hormone-producing cells throughout life. Signals from inside and outside the gland control how the pituitary develops and maintain the correct balance of different types of cells in the gland in adults.</p><p>In 2016, Lodge et al. reported that a cascade of signals known as the Hippo pathway is active in mouse and human pituitary glands, but its role remained unclear. Here, Lodge et al. use genetic approaches to study this signalling pathway in the pituitary of mice.</p><p>The results of the experiments show that the Hippo pathway is essential for the pituitary gland to develop normally in mouse embryos. Furthermore, in adult mice the Hippo pathway is required to maintain the population of SOX2 cells in the pituitary and to regulate their cell numbers. Increasing the level of Hippo signalling in mouse embryos and adult mice led to an expansion of SOX2 stem cells that could generate new specialist cell types, but a further increase generated aggressive tumours that originated from the uncontrolled growth of SOX2 cells.</p><p>These findings are the first step to understanding how the Hippo pathway works in the pituitary, which may eventually lead to new treatments for tumours and other diseases that affect this gland. The next step towards such treatments will be to carry out further experiments that use drugs to control this pathway and alter the fate of pituitary cells in mice and other animals.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>pituitary stem cell</kwd><kwd>SOX2</kwd><kwd>Hippo</kwd><kwd>YAP</kwd><kwd>pituitary tumour</kwd><kwd>LATS</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000380</institution-id><institution>Guy's and St Thomas' Charity</institution></institution-wrap></funding-source><award-id>Prize PhD Programme</award-id><principal-award-recipient><name><surname>Lodge</surname><given-names>Emily J</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009360</institution-id><institution>King’s College London</institution></institution-wrap></funding-source><award-id>Dianna Trebble Endowment Fund Dental Institute Studentship</award-id><principal-award-recipient><name><surname>Russell</surname><given-names>John P</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>GRK 2251</award-id><principal-award-recipient><name><surname>Bornstein</surname><given-names>Stefan R</given-names></name><name><surname>Andoniadou</surname><given-names>Cynthia Lilian</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>CRC/Transregio 205/1</award-id><principal-award-recipient><name><surname>Bornstein</surname><given-names>Stefan R</given-names></name><name><surname>Andoniadou</surname><given-names>Cynthia Lilian</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/L016729/1</award-id><principal-award-recipient><name><surname>Andoniadou</surname><given-names>Cynthia Lilian</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001255</institution-id><institution>Lister Institute of Preventive Medicine</institution></institution-wrap></funding-source><award-id>Prize Fellowship 2016</award-id><principal-award-recipient><name><surname>Andoniadou</surname><given-names>Cynthia Lilian</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The LATS/YAP/TAZ cascade promotes SOX2+ pituitary stem cell fate and when over-activated, transforms normal stem cells into cancer stem cells.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>SOX2 is a crucial transcription factor involved in the specification and maintenance of multiple stem cell populations in mammals. Pituitary stem cells express SOX2 and contribute to the generation of new endocrine cells during embryonic development and throughout postnatal life (<xref ref-type="bibr" rid="bib4">Andoniadou et al., 2013</xref>; <xref ref-type="bibr" rid="bib44">Rizzoti et al., 2013</xref>). The pituitary gland is composed of three parts, the anterior, intermediate and posterior lobes (AL, IL and PL, respectively). The AL and IL contain hormone-secreting cells, which are derived from an evagination of the oral ectoderm expressing SOX2, termed Rathke’s pouch (RP). SOX2+ cells, both in the embryonic and adult pituitary, can differentiate into three endocrine cell lineages, which are marked by transcription factors PIT1 (POU1F1) (<xref ref-type="bibr" rid="bib26">Li et al., 1990</xref>), TPIT (TBX19) (<xref ref-type="bibr" rid="bib43">Pulichino et al., 2003</xref>) and SF1 (NR5A1) (<xref ref-type="bibr" rid="bib19">Ingraham et al., 1994</xref>), and differentiate into hormone-secreting cells (somatotrophs, lactotrophs, thyrotrophs, corticotrophs, melanotrophs and gonadotrophs, which express growth hormone, prolactin, thyrotropin, adrenocorticotropin, melanotropin and gonadotropin, respectively). SOX2+ PSCs are highly proliferative during the first 2–3 weeks of life, in concordance with major organ growth, after which they reach a steady low proliferative capacity that contributes to maintain normal homeostasis and physiological adaptation of the pituitary gland (<xref ref-type="bibr" rid="bib24">Levy, 2002</xref>; <xref ref-type="bibr" rid="bib37">Nolan et al., 1998</xref>).</p><p>Contrary to other organs, where somatic stem cells are shown to be able to become transformed into cancer stem cells, the roles of SOX2+ PSCs in tumourigenesis remain poorly understood, possibly due to the patchy knowledge of the pathways regulating SOX2+ PSC fate and proliferation. Pituitary tumours are common in the population, representing 10–15% of all intracranial neoplasms (<xref ref-type="bibr" rid="bib7">Bronstein et al., 2011</xref>; <xref ref-type="bibr" rid="bib11">Daly et al., 2006</xref>). Adenomas are the most common adult pituitary tumours, classified into functioning, when they secrete one or more of the pituitary hormones, or non-functioning if they do not secrete hormones. In children, adamantinomatous craniopharyngioma (ACP) is the most common pituitary tumour. Targeting oncogenic beta-catenin in SOX2+ PSCs in the mouse generates clusters of senescent SOX2+ cells that induce tumours resembling ACP in a paracrine manner, that is the tumours do not derive from the targeted SOX2+ PSCs (<xref ref-type="bibr" rid="bib4">Andoniadou et al., 2013</xref>; <xref ref-type="bibr" rid="bib14">Gonzalez-Meljem et al., 2017</xref>). Up to 15% of adenomas and 50% of ACP display aggressive behaviour with invasion of nearby structures including the hypothalamus and visual tracts, associated with significant morbidity and mortality (<xref ref-type="bibr" rid="bib21">Lasolle et al., 2017</xref>). Pituitary carcinomas exhibiting metastasis are rare but can develop from benign tumours (<xref ref-type="bibr" rid="bib54">Veldhuis, 2013</xref>; <xref ref-type="bibr" rid="bib42">Pernicone et al., 1997</xref>; <xref ref-type="bibr" rid="bib17">Heaney, 2014</xref>). Whether SOX2+ cells can cell autonomously contribute to pituitary neoplasia has not been hitherto demonstrated.</p><p>The Hippo pathway controls stem cell proliferation and tumourigenesis in several organs such as in the liver (<xref ref-type="bibr" rid="bib59">Zhou et al., 2009</xref>; <xref ref-type="bibr" rid="bib30">Lu et al., 2018</xref>), intestines (<xref ref-type="bibr" rid="bib60">Zhou et al., 2011</xref>) and lung (<xref ref-type="bibr" rid="bib27">Lin et al., 2015</xref>; <xref ref-type="bibr" rid="bib36">Nantie et al., 2018</xref>). In the core phosphorylation cascade, STK3/4 kinases phosphorylate and activate LATS1/2 serine/threonine-protein kinases, which in turn phosphorylate co-activators Yes-associated protein (YAP1, a.k.a. YAP) and WW domain-containing transcription regulator protein 1 (WWTR1, a.k.a. TAZ) that are subsequently inactivated through degradation and cytoplasmic retention (<xref ref-type="bibr" rid="bib32">Meng et al., 2016</xref>). Active YAP/TAZ associate with TEAD transcription factors, promoting the transcription of target genes such as <italic>Cyr61</italic> and <italic>Ctgf</italic> (<xref ref-type="bibr" rid="bib58">Zhao et al., 2008</xref>; <xref ref-type="bibr" rid="bib57">Zhang et al., 2009</xref>; <xref ref-type="bibr" rid="bib61">Zhou et al., 2016</xref>). YAP/TAZ have been shown to promote proliferation and the stem cell state in several organs, and can also lead to transformation and tumour initiation when overexpressed (<xref ref-type="bibr" rid="bib8">Camargo et al., 2007</xref>; <xref ref-type="bibr" rid="bib48">Schlegelmilch et al., 2011</xref>; <xref ref-type="bibr" rid="bib12">Dong et al., 2007</xref>). The involvement of YAP/TAZ in the function of tissue-specific SOX2+ stem cells during development and homeostasis has not been shown. We previously reported strong nuclear localisation of YAP and TAZ exclusively in SOX2+ stem cells of developing Rathke's pouch and the postnatal anterior pituitary of mice and humans, and enhanced expression in human pituitary tumours composed of uncommitted cells, including ACPs and null-cell adenomas (<xref ref-type="bibr" rid="bib28">Lodge et al., 2016</xref>; <xref ref-type="bibr" rid="bib55">Xekouki et al., 2019</xref>), which do not express any of the lineage transcription factors PIT1, TPIT or SF1. In these populations we detected phosphorylation of YAP at serine 127 (S127) indicating LATS kinase activity. Together these point to a possible function for LATS/YAP/TAZ in normal pituitary stem cells and during tumourigenesis. Here, we have combined genetic and molecular approaches to reveal that deregulation of the pathway can promote and maintain the SOX2+ PSC fate under physiological conditions and that major disruption of this axis transforms SOX2+ PSCs into cancer-initiating cells giving rise to aggressive tumours.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Sustained conditional expression of YAP during development promotes SOX2+ PSC fate</title><p>To determine if YAP and TAZ function during embryonic development of the pituitary, we used genetic approaches to perform gain- and loss-of-function experiments. We first expressed a constitutive active form of YAP(S127A) using the <italic>Hesx1-Cre</italic> driver, which drives <italic>Cre</italic> expression in Rathke’s pouch (RP) and the hypothalamic primordium from 9.5dpc, regulated by administration of doxycycline through the reverse tetracycline-dependent transactivator (rtTA) system (<italic>R26<sup>rtTA/+</sup></italic>; see Materials and methods for details, Scheme <xref ref-type="fig" rid="fig1">Figure 1A</xref>). Analyses were restricted to embryonic time points. As expected, we confirmed accumulation of total YAP protein but not of TAZ or pYAP(S127), throughout the developing pituitary and hypothalamus of <italic>Hesx1<sup>Cre/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> (hereafter YAP-TetO) embryos at 15.5dpc, but not of <italic>Cre</italic>-negative controls (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Likewise, the YAP downstream target <italic>Cyr61</italic> (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) was also upregulated. Morphologically, YAP-TetO mutants displayed a dysplastic anterior pituitary, which was more medially compacted and lacked a central lumen, making it difficult to distinguish between the developing anterior and intermediate lobes (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Immunofluorescence staining against SOX2 at 15.5dpc demonstrated loss of SOX2 in the most lateral regions of control pituitaries (arrows in <xref ref-type="fig" rid="fig1">Figure 1C</xref>), where cells are undergoing commitment; yet mutant pituitaries had abundant SOX2 positive cells in the most lateral regions (arrowheads in <xref ref-type="fig" rid="fig1">Figure 1C</xref>). Immunostaining for LHX3, which is expressed in the developing anterior pituitary (<xref ref-type="bibr" rid="bib49">Sheng et al., 1996</xref>), was used to demarcate AL and IL tissue. Staining using antibodies against lineage markers PIT1, TPIT and SF1 revealed a concomitant reduction in committed cell lineages throughout the gland (<xref ref-type="fig" rid="fig1">Figure 1D</xref>; PIT1 0.35% in mutants compared with 30.21% in controls (Student’s t-test p&lt;0.0001, n = 3 for each genotype), TPIT 1.03% in mutants compared with 9.81% in controls (Student’s t-test p=0.0012, n = 3 for each genotype), SF1 0.34% in mutants compared with 4.14% in controls (Student’s t-test p=0.0021, n = 3 for each genotype)). We therefore conclude that sustained activation of YAP prevents lineage commitment and is sufficient to maintain the progenitor state during embryonic development.</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.43996.003</object-id><label>Figure 1.</label><caption><title>Regulation of YAP is required for normal morphogenesis and lineage commitment during pituitary development.</title><p>(<bold>A</bold>) Schematic outlining the time course of doxycycline (DOX) treatment administered to pregnant dams from <italic>Hesx1<sup>Cre/+</sup></italic> x <italic>R26<sup>rtTA/rtTA</sup>;Col1a1<sup>tetO-Yap/tetO-Yap</sup></italic> crosses for the embryonic induction of YAP(S127A) expression in <italic>Hesx1<sup>Cre/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> (YAP-TetO) mutant embryos as well as controls that do not express YAP(S127A) (<italic>Hesx1<sup>+/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> controls shown here). (<bold>B</bold>) Immunofluorescence staining against YAP and TAZ on frontal pituitary sections at 15.5dpc confirms accumulation of YAP protein in YAP-TetO compared to control sections, but no increase in TAZ levels. RNAscope mRNA in situ hybridisation against the YAP/TAZ target <italic>Cyr61</italic> confirms an increase in transcripts in the anterior pituitary as well as the hypothalamus where the Cre is also active (arrows). (<bold>C</bold>) Haematoxylin and eosin staining of frontal pituitary sections from 15.5dpc control and YAP-TetO embryos showing pituitary dysmorphology in mutants. Immunofluorescence staining for LHX3 to mark anterior pituitary tissue and SOX2 to mark pituitary progenitors shows the persistence of SOX2 protein in lateral regions of the gland in YAP-TetO mutants (arrowheads) when they have lost SOX2 expression in controls (arrows) (magnified boxed region in SOX2, corresponding to dashed box in LHX3). (<bold>D</bold>) Immunofluorescence staining for lineage-committed progenitor markers PIT1, TPIT and SF1 reveals very few cells expressing commitment markers in YAP-TetO compared to control. Graph showing quantification of committed cells of the three anterior pituitary endocrine lineages, positive for PIT1, TPIT and SF1, as a percentage of total nuclei of <italic>Hesx1<sup>+/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> control and <italic>Hesx1<sup>Cre/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> (YAP-TetO) mutant pituitaries at 15.5dpc (Student’s <italic>t</italic>-test; PIT1: p&lt;0.0001 (****), TPIT: p=0.0012 (**), SF1: p=0.0021 (**)). Scale bars 100 µm, 50 µm in magnified boxed regions in C. See also <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplements 1 </xref><xref ref-type="fig" rid="fig1s2">and 2</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43996-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.43996.004</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Regulation of YAP and TAZ during pituitary development.</title><p>(<bold>A</bold>) Hematoxylin and eosin staining on frontal sections through the pituitary from control and YAP-TetO heads after DOX treatment from 5.5dpc until 15.5dpc. (<bold>B</bold>) Schematic outlining the time course of doxycycline (DOX) treatment administered to <italic>Hesx1<sup>Cre/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> (YAP-TetO) and <italic>Hesx1<sup>+/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> controls to drive expression of YAP-S127A in mutant pituitaries during embryonic as well as postnatal development. (<bold>C</bold>) Hematoxylin and eosin (H and E) staining of control and YAP-TetO pituitaries at P24. Higher magnification images show the presence of cysts in the YAP-TetO mutant. White arrows indicate cells with enlarged nuclei surrounding the cysts and yellow arrowheads indicate ciliated cells. (<bold>D</bold>) Immunofluorescence staining against total YAP on frontal sections at P24 confirms accumulation of YAP protein in YAP-TetO compared to control sections, especially in the ventral anterior lobe. Immunofluorescence staining against SOX2 shows an expansion of SOX2+ epithelia lining cysts. (<bold>E</bold>) Immunofluorescence staining for lineage-committed progenitor markers PIT1, SF1 and of ACTH marking cells of the TPIT lineage in control and YAP-TetO sections at P24. The number of SOX2+ and lineage-committed cells is quantified in the graph below. Note there is a significant increase in the proportion of SOX2+ cells in YAP-TetO mutants (Student’s <italic>t</italic>-test, p&lt;0.0001 (****)), decrease in PIT1+ cells (Student’s <italic>t</italic>-test, p&lt;0.0002 (***)), increase in SF1+ cells (Student’s <italic>t</italic>-test, p&lt;0.0066 (**)) and no significant change in ACTH+ cells. (<bold>F</bold>) Immunofluorescence staining against Ki-67 marking cycling cells in control and YAP-TetO sections at P24. Graph showing the percentage of Ki-67+ cells across total anterior pituitary cells. There is a trend towards a reduction in the proportion of cycling cells in YAP-TetO mutants, which is not significant (Student’s <italic>t</italic>-test, p&gt;0.05). (<bold>G</bold>) Immunohistochemistry using antibodies against p63 and the AE1/AE3 cytokeratin cocktail in YAP-TetO mutants at P24 revealing positive cells lining the cysts (arrowheads). (<bold>H</bold>) Immunofluorescence staining using antibodies against ARL13B and Acetylated α-Tubulin, staining components of cilia, reveals ciliated cells lining the cysts. Staining for Alcian Blue and Period Acid Schiff (AB/PAS) to differentiate between acidic and neutral mucins reveals royal blue-stained mucous cells lining the cysts. Scale bars 1 mm in A, 500 µm in C and 100 µm in magnified panels in C, 100 µm in D, E, F and 50 µm in G and H.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43996-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.43996.005</object-id><label>Figure 1—figure supplement 2.</label><caption><title>Regulation of YAP and TAZ during pituitary development.</title><p>(<bold>A</bold>) Hematoxylin and eosin staining on sagittal pituitary sections of 13.5dpc <italic>Hesx1<sup>Cre/+</sup>;Yap<sup>fl/fl</sup>;Taz<sup>-/-</sup></italic> (mutant) and <italic>Hesx1<sup>+/+</sup>;Yap<sup>fl/+</sup>;Taz<sup>+/-</sup></italic> (control) showing comparable morphology. (<bold>B</bold>) Immunofluorescence staining using antibodies against SOX2 in <italic>Hesx1<sup>Cre/+</sup>;Yap<sup>fl/fl</sup>;Taz<sup>-/-</sup></italic> and control at 13.5dpc (sagittal) and 16.5dpc (frontal) showing the presence of SOX2+ cells in both genotypes. (<bold>C</bold>) Immunofluorescence staining for SOX2, Endomucin (EMCN) and active YAP in P28 <italic>Hesx1<sup>Cre/+</sup>;Yap<sup>fl/fl</sup>;Taz<sup>-/-</sup></italic> and control pituitaries, identifies SOX2+ cells in regions that are negative for active YAP (mice are null for TAZ) and reveals normal vasculature. (<bold>D</bold>) Graph quantifying the percentage of SOX2+ cells expressing active YAP in control and <italic>Hesx1<sup>Cre/+</sup>;Yap<sup>fl/fl</sup>;Taz<sup>-/-</sup></italic> mutant pituitaries at P28. There is a reduction in double-positive cells in the mutant, which did not reach significance. (<bold>E</bold>) Immunofluorescence staining for lineage committed progenitor markers PIT1 and SF1, as well as ACTH marking corticotrophs (TPIT lineage), reveals the presence and normal localisation of cells from the three lineages in a P28 <italic>Hesx1<sup>Cre/+</sup>;Yap<sup>fl/fl</sup>;Taz<sup>-/-</sup></italic> mutant. Scale bars 100 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43996-fig1-figsupp2-v2.tif"/></fig></fig-group><p>We did not obtain any live <italic>Hesx1<sup>Cre/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> pups at birth when treated with doxycycline from 5.5dpc (n = 5 litters). To bypass the embryonic lethality of these early inductions, we commenced doxycycline treatment from 9.5dpc, the onset of RP formation (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>).</p><p><italic>Hesx1<sup>Cre/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> pups were viable and were maintained on doxycycline until P24, at which point the experimental end point was reached due to excessive weight loss and animals had to be culled following UK Home Office Regulations. Histological analyses of pituitaries revealed multiple anterior lobe cysts per gland, localising predominantly in the ventral AL (n = 4) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). These structures developed in YAP-accumulating regions and were lined by SOX2+ cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). The proportion of SOX2+ cells throughout the AL was increased, as was the percentage of SF1+ cells, whereas PIT1+ cell numbers were significantly decreased and differentiated cells of the TPIT lineage, identified by ACTH antibody staining, were unaffected (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>). The total number of cycling Ki-67+ cells showed a trend towards a decrease in <italic>Hesx1<sup>Cre/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> mutants relative to controls, which did not reach significance (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F</xref>). The cystic structures observed in <italic>Hesx1<sup>Cre/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> mutants were reminiscent of Rathke’s cleft cyst (RCC), which is a benign developmental anomaly of the pituitary characterised by the presence of ciliated and secretory cells, expression of cytokeratins and frequent expression of p63. Immunostaining revealed that cysts were lined by cytokeratin+ cells using the AE1/AE3 pan-cytokeratin cocktail and basal cells were positive for nuclear p63 in <italic>Hesx1<sup>Cre/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> mutant pituitaries (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G</xref>). Staining using antibodies against ARL13B and Acetylated α-Tubulin (Lys40) marking cilia, revealed multi-ciliated cells along the cyst lining (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1H</xref>). Combined staining using Alcian Blue and the Periodic Acid-Schiff technique (AB/PAS) to recognise mucins, detected royal blue-stained mucous cells lining the cysts (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1H</xref>). Taken together, we conclude that sustained activation of YAP during embryonic and postnatal pituitary development, promotes maintenance and abnormal expansion of SOX2+ epithelia during development, resulting in the formation of cysts that resemble RCC.</p><p>Next, we generated embryos null for TAZ and conditionally lacking YAP in the <italic>Hesx1</italic> expression domain (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A–E</xref>). <italic>Hesx1<sup>Cre/+</sup>;Yap<sup>fl/fl</sup>;Taz<sup>-l-</sup></italic> double mutants were obtained at expected ratios during embryonic stages until 15.5dpc, however the majority of <italic>Taz<sup>-/-</sup></italic> mutants with or without compound <italic>Yap</italic> deletions showed lethality at later embryonic and early postnatal stages (<xref ref-type="bibr" rid="bib52">Tian et al., 2007</xref>) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). The developing pituitary gland of <italic>Hesx1<sup>Cre/+</sup>;Yap<sup>fl/fl</sup>;Taz<sup>-l-</sup></italic> double mutants appeared largely normal at 13.5dpc by histology (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). Immunostaining against SOX2 to mark embryonic progenitors and postnatal stem cells did not reveal differences in the spatial distribution of SOX2+ cells between double mutants compared to controls (<italic>Hesx1<sup>+/+</sup>;Yap<sup>fl/fl</sup>;Taz<sup>+/+</sup></italic> and <italic>Hesx1<sup>+/+</sup>;Yap<sup>fl/fl</sup>;Taz<sup>+/-</sup></italic>) at 13.5dpc, 16.0dpc (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B</xref>) or P28, even in regions devoid of both TAZ and active YAP (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C,D</xref>). This suggests that YAP/TAZ are not required for SOX2+ cell specification or survival. Likewise, analysis of commitment markers PIT1 and SF1 as well as ACTH to identify cells of the TPIT lineage, did not show any differences between genotypes (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2E</xref>). Together, these data suggest there is no critical requirement for YAP and TAZ during development for the specification of SOX2+ cells or lineage commitment, but that YAP functions to promote the SOX2 cell identity.</p></sec><sec id="s2-2"><title>LATS, but not STK, kinases are required for normal pituitary development and differentiation</title><p>Since sustained activation of YAP led to an embryonic phenotype, we reasoned that YAP/TAZ need to be regulated during embryonic development. To determine if STK and LATS kinases are important in YAP/TAZ regulation we carried out genetic deletions in the pituitary.</p><p>Conditional deletion of <italic>Stk3</italic> and <italic>Stk4</italic> (also called <italic>Mst2</italic> and <italic>Mst1</italic>) in <italic>Hesx1<sup>Cre/+</sup>;Stk3<sup>fl/fl</sup>;Stk4<sup>fl/fl</sup></italic> embryos did not lead to a pituitary phenotype (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). A reduction of over 75% in total STK3/4 proteins in mutants was confirmed by western blot on total lysates from <italic>Hesx1<sup>+/+</sup></italic>;<italic>Stk3<sup>fl/fl</sup>;Stk4<sup>fl/fl</sup></italic> controls and <italic>Hesx1<sup>Cre/+</sup>;Stk3<sup>fl/fl</sup>;Stk4<sup>fl/fl</sup></italic> mutants (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Mutant pituitaries were macroscopically normal at birth (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>), and showed comparable expression patterns of TAZ, YAP, pYAP to controls lacking <italic>Cre</italic>, without distinct accumulation of YAP or TAZ (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). The distribution of SOX2+ cells was comparable between mutants and controls (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). Normal lineage commitment was evident by immunofluorescence staining for PIT1, TPIT and SF1 at P10 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). Mutant animals remained healthy and fertile until P70, at which point pituitaries appeared histologically normal (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>). Since deletion of <italic>Stk3/4</italic> at embryonic stages does not affect embryonic or postnatal pituitary development, we conclude these kinases are not critical for YAP/TAZ regulation in the pituitary.</p><fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.43996.006</object-id><label>Figure 2.</label><caption><title>Pituitary-specific deletion of <italic>Lats1</italic> and <italic>Lats2</italic> during development leads to pituitary overgrowth and defects in lineage commitment.</title><p>(<bold>A</bold>) Haematoxylin and eosin staining on sagittal sections from <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/fl</sup></italic> (mutant) and <italic>Hesx1<sup>+/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/fl</sup></italic> (control) embryos at 13.5dpc reveals anterior pituitary dysmorphology and overgrowth in mutants (dashed outline). Immunofluorescence staining for TAZ, YAP and pYAP reveals accumulation of TAZ and YAP in overgrown mutant tissue (arrowheads, normal epithelial expression indicated by arrows in control) and lack of staining for pYAP (S127). Immunofluorescence for SOX2 shows the presence of SOX2+ progenitors throughout the abnormal tissue in mutants. (<bold>B</bold>) Immunofluorescence staining for late progenitor marker SOX9 shows localisation in few cells of the pituitary of mutants at 13.5dpc. Immunofluorescence staining for Ki-67 indicates cycling cells throughout the mutant pituitary. (<bold>C</bold>) Immunofluorescence staining for SOX2 and Endomucin (EMCN) on frontal pituitary sections at 15.5dpc shows expansion of the SOX2+ progenitor compartment compared to controls and a reduction in vasculature marked by Endomucin. Immunofluorescence for non-phosphorylated (Active) YAP shows strong expression throughout the mutant gland compared to the control. Areas of necrosis in mutant tissue indicated by asterisks. Ventral overgrowth extending into the oral cavity between the condensing sphenoid bone indicated by arrows. (<bold>D</bold>) Immunofluorescence staining for lineage-committed progenitor markers PIT1, TPIT and SF1 reveals only sporadic cells expressing commitment markers in <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/fl</sup></italic> mutants compared to controls. Boxes showing magnified regions. Dashed lines demarcate anterior pituitary tissue. Graph showing quantification of committed cells of the three anterior pituitary endocrine lineages, positive for PIT1, TPIT and SF1, as a percentage of total nuclei of <italic>Hesx1<sup>+/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/fl</sup></italic> control and <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/fl</sup></italic> mutant pituitaries at 15.5dpc (Student’s <italic>t</italic>-test; PIT1: p&lt;0.0001 (****), TPIT: p=0.007 (**), SF1: p&gt;0.05). Scale bars 100 µm. See also <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43996-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.43996.007</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Pituitary-specific loss of <italic>Stk3</italic> and <italic>Stk4</italic> does not affect SOX2 cell specification or lineage commitment.</title><p>(<bold>A</bold>) Dorsal view of wholemount <italic>Hesx1<sup>Cre/+</sup>;Stk3<sup>fl/fl</sup>;Stk4<sup>fl/fl</sup></italic> (mutant) and <italic>Hesx1<sup>+/+</sup></italic>;<italic>Stk3<sup>fl/fl</sup>;Stk4<sup>fl/fl</sup></italic> (control) pituitaries at P0 showing comparable morphology and size at birth. (<bold>B</bold>) Western blot to determine levels of STK3 and STK4 proteins in <italic>Hesx1<sup>Cre/+</sup>;Stk3<sup>fl/fl</sup>;Stk4<sup>fl/fl</sup></italic> mutant pituitaries compared to controls at P35, using an antibody against total STK3 and STK4 proteins. Comparison of STK3/4 band intensities confirms a significant reduction in mutants (Student’s <italic>t</italic>-test, p=0.00032 (***)). STK3/4 bands normalised to the housekeeping protein Cyclophilin B. (<bold>C</bold>) Immunofluorescence staining using antibodies against SOX2, TAZ, Endomucin (EMCN), YAP and pYAP at P0, indicating comparable staining between control and mutant samples. (<bold>D</bold>) Immunofluorescence staining against lineage commitment markers PIT1, TPIT and SF1 shows normal lineage commitment in a <italic>Hesx1<sup>Cre/+</sup>;Stk3<sup>fl/fl</sup>;Stk4<sup>fl/fl</sup></italic> mutant pituitary compared to the control at P10. (<bold>E</bold>) Hematoxylin and eosin staining through frontal sections of <italic>Hesx1<sup>Cre/+</sup>;Stk3<sup>fl/fl</sup>;Stk4<sup>fl/fl</sup></italic> and control pituitaries at P70. AL: anterior lobe, IL: intermediate lobe, PL: posterior lobe. Scale bars 100 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43996-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.43996.008</object-id><label>Figure 2—figure supplement 2.</label><caption><title>Isolated deletions of <italic>Lats1</italic> or <italic>Lats2</italic> in the pituitary do not affect development.</title><p>(<bold>A</bold>) Hematoxylin and eosin staining of a sagittal section of <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup></italic> at 13.5dpc showing normal morphology (see <xref ref-type="fig" rid="fig2">Figure 2A</xref> for control). Dashed lines demarcate developing Rathke’s pouch. Immunofluorescence staining for TAZ and YAP reveals a normal expression pattern and no gross protein accumulation (compare to control, <xref ref-type="fig" rid="fig2">Figure 2A</xref>). (<bold>B</bold>) Dorsal view of wholemount <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup></italic> (mutant) and <italic>Hesx1<sup>Cre/+</sup></italic> (control) pituitaries at P0 showing comparable morphology and size at birth. (<bold>C</bold>) RNAscope mRNA in situ hybridisation against <italic>Lats2</italic> shows an increase in transcripts in the anterior pituitary following deletion of <italic>Lats1</italic> (<italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup></italic>) compared to control (<italic>Hesx1<sup>Cre/+</sup></italic>), where <italic>Lats2</italic> expression is barely detectable. (<bold>D</bold>) Hematoxylin and eosin staining of a sagittal section of <italic>Hesx1<sup>Cre/+</sup>;Lats2<sup>fl/fl</sup></italic> at 13.5dpc showing normal morphology (see <xref ref-type="fig" rid="fig2">Figure 2A</xref> for control). Dashed lines demarcate developing Rathke’s pouch. (<bold>E</bold>) Hematoxylin and eosin staining on frontal sections through 15.5dpc embryonic heads of <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/fl</sup></italic> (mutant) and control (<italic>Hesx1<sup>+/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/fl</sup></italic>) genotypes, at the levels indicated in the cartoon. Note the hyperplastic pituitary at both axial levels, exerting mass effect on the brain. Asterisk indicates necrosis. Graph showing quantification of pituitary size at 15.5dpc as measured by the area occupied by the pituitary in matched histological sections between control and mutant embryos. <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/fl</sup></italic> mutant pituitaries are significantly larger (average 0.7195 mm<sup>2</sup>) compared to controls (average 0.1994 mm<sup>2</sup>) (Student’s <italic>t</italic>-test, p=0.0003 (***)). (<bold>F</bold>) Quantification of Ki-67+ and SOX9+ cells across the whole Rathke’s pouch of <italic>Hesx1<sup>Cre/+</sup></italic> (control) and <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup></italic> (mutant) pituitaries at 13.5dpc. There is a significant increase in cycling cells in mutants, marked by Ki-67 (Student’s <italic>t</italic>-test, p=0.0067 (**)). The proportion of SOX9+ cells is comparable between genotypes. Scale bars 100 µm in A-D, 1 mm in E.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43996-fig2-figsupp2-v2.tif"/></fig></fig-group><p>We next focused on perturbing LATS kinase function, as we have previously shown strong expression of <italic>Lats1</italic> in the developing pituitary and postnatal kinase activity in SOX2+ stem cells (<xref ref-type="bibr" rid="bib28">Lodge et al., 2016</xref>). However, <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup></italic> embryos showed unaffected pituitary development and normal localisation and levels of YAP and TAZ as assessed by immunofluorescence (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A,B</xref>) when compared with controls. mRNA in situ hybridisation against <italic>Lats2</italic> at P2, revealed abundant <italic>Lats2</italic> transcripts upon conditional deletion of <italic>Lats1</italic>, suggesting a compensatory upregulation of <italic>Lats2</italic> in the absence of LATS1 (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref>), similar to previous reports of elevated YAP/TAZ signalling inducing <italic>Lats2</italic> expression (<xref ref-type="bibr" rid="bib33">Moroishi et al., 2015</xref>).</p><p>To overcome potential functional redundancy, we deleted both <italic>Lats1</italic> and <italic>Lats2</italic> in RP. Deletion of <italic>Lats2</italic> alone (<italic>Hesx1<sup>Cre/+</sup>;Lats2<sup>fl/fl</sup></italic>), did not reveal any developmental morphological anomalies (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D</xref>) and pups were identified at normal Mendelian proportions (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Similarly, deletion of any three out of four <italic>Lats</italic> alleles did not affect pituitary development and were identified at normal ratios, similar to other tissues (<xref ref-type="bibr" rid="bib22">Lavado et al., 2018</xref>). Homozygous <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/fl</sup></italic> mutants were identified at embryonic stages at reduced Mendelian ratios and were absent at P0-P2, suggesting embryonic and perinatal lethality (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>).</p><p>Haematoxylin/eosin staining of the developing pituitary gland in <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/fl</sup></italic> mutants revealed overgrowth of RP by 13.5dpc compared to controls lacking <italic>Cre</italic> (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, n = 4). Total TAZ and YAP proteins accumulated throughout the developing gland in double mutants (arrowheads) but only in the SOX2+ periluminal epithelium of controls (arrows). The same regions showed a marked reduction in pYAP-S127 staining, which is observed in SOX2+ cells of the control (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). These findings are in line with LATS1/2 normally regulating YAP and TAZ in the pituitary and demonstrate successful deletion in RP. The mutant pituitary was highly proliferative (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2F</xref>; Ki-67 index average 47.42% ± 1.73 SEM in control versus 76.04% ± 9.11 SEM in the double mutant, p=0.0067, Student’s <italic>t</italic>-test) and the majority of cells expressed SOX2 (<xref ref-type="fig" rid="fig2">Figure 2A,C</xref>) but not SOX9 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2F</xref>).</p><p>By 15.5dpc the pituitary was grossly enlarged and exerting a mass effect on the brain, had cysts and displayed areas of necrosis (asterisks <xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2E</xref>, n = 5). Staining for Endomucin to mark blood vessels revealed poor vascularisation in <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/fl</sup></italic> mutants compared to the ample capillaries seen in the control (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), which may account for the necrosis. This could be due to a direct inhibition of vascularisation or a consequence of the rapid growth of this embryonic tumour. We frequently observed ectopic residual pituitary tissue at more caudal levels, reaching the oral epithelium and likely interfering with appropriate fusion of the sphenoid, similar to other phenotypes involving pituitary enlargement (arrows <xref ref-type="fig" rid="fig2">Figure 2C</xref>) (<xref ref-type="bibr" rid="bib3">Andoniadou et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">Sajedi et al., 2008</xref>; <xref ref-type="bibr" rid="bib13">Gaston-Massuet et al., 2008</xref>). Immunofluorescence to detect active (non-phosphorylated) YAP revealed abundant staining throughout the pituitary at 15.5dpc, compared to the control where active YAP localises in the SOX2 epithelium (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Immunofluorescence using specific antibodies against lineage commitment markers PIT1, TPIT and SF1 at 15.5dpc revealed very few cells expressing PIT1, TPIT and SF1 in the double mutant (<xref ref-type="fig" rid="fig2">Figure 2D</xref>; PIT1 9.14% in mutants compared with 51.4% in controls (Student’s <italic>t</italic>-test p&lt;0.0001); TPIT 4.0% in mutants compared with 11.4% in controls (Student’s <italic>t</italic>-test p&lt;0.007); SF1 2.1% in mutants compared with 6.5% in controls (Student’s <italic>t</italic>-test p&gt;0.05) n = 3 mutants and five controls), suggesting failure to commit into the three lineages. These data suggest that the LATS/YAP/TAZ axis is required for normal embryonic development of the anterior pituitary and that LATS1/2 kinases control proliferation of SOX2+ progenitors and their progression into the three committed lineages.</p></sec><sec id="s2-3"><title>Loss of LATS kinases results in carcinoma-like murine tumours</title><p>Postnatal analysis of <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup></italic> pituitaries revealed that by P56, despite developing normally during the embryonic period, all glands examined exhibited lesions of abnormal morphology consisting of overgrowths, densely packed nuclei and loss of normal acinar architecture (n = 15). To minimise the likely redundancy by LATS2 seen at embryonic stages, we generated <italic>Lats1</italic> mutants additionally haploinsufficient for <italic>Lats2</italic> (<italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic>). These pituitaries also developed identifiable lesions accumulating YAP and TAZ (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>), which were observed at earlier time points (P21 n = 4), the earliest being 10 days, indicating increased severity. The number of lesions observed per animal was similar between the two models at P56 (3–8 per animal). Deletion of <italic>Lats2</italic> alone (<italic>Hesx1<sup>Cre/+</sup>;Lats2<sup>fl/fl</sup></italic>), which is barely expressed in the wild type pituitary, did not result in any defects (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). We focused on the <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> double mutants for further analyses.</p><p>Histological examination of <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> pituitaries confirmed the abnormal lesions were tumours, characterised by frequent mitoses, focal necrosis, and a focal squamous differentiation, as well as the occasional presence of cysts (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). These lesions were identical to those in <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup></italic> pituitaries (not shown). These tumours accumulated YAP/TAZ and upregulated expression of targets <italic>Cyr61</italic> and <italic>Ctgf</italic> (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), confirming the validity of the genetic manipulation (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Tumours were also frequently observed in the anterior and intermediate lobe (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). Analysis of proliferation by Ki-67 immunostaining revealed an elevated mitotic index of 7–28% in tumours (mean 15.46, SEM ±2.74), compared to 2.97% (SEM ±1.2) mean in control pituitaries not carrying the <italic>Lats1</italic> deletion (<xref ref-type="fig" rid="fig3">Figure 3C</xref>).</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.43996.009</object-id><label>Figure 3.</label><caption><title>Pituitary specific loss of <italic>Lats1</italic> leads to tumour formation.</title><p>(<bold>A</bold>) Haematoxylin and eosin staining of frontal sections from <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> (mutant) and control pituitaries at P56 demonstrates overgrown tumourigenic regions in mutants. These show focal necrosis, cysts and a squamous morphology (magnified regions) not seen in controls. Asterisk indicates necrosis. (<bold>B</bold>) Immunofluorescence staining for TAZ, YAP and pYAP(S127) show accumulation of TAZ and YAP but not pYAP in the mutant but not in the control. RNAscope mRNA in situ hybridisation against YAP/TAZ targets <italic>Ctgf</italic> and <italic>Cyr61</italic> reveals an increase in transcripts on mutant tissue compared to control. (<bold>C</bold>) Graph of the proliferation index in control and mutant samples at P56 shows a significant increase in cycling cells in the <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> mutant pituitaries compared to controls (control percentage Ki-67: 2.967 ± 1.2 SEM, n = 3; mutant: 15.46 ± 2.74 n = 7. p=0.0217 (*), two-tailed <italic>t</italic>-test). Images show representative examples of Ki-67 immunofluorescence staining. (<bold>D</bold>) Immunofluorescence staining for lineage-committed progenitor markers PIT1, TPIT and SF1 shows the near absence of committed cells in tumours. (<bold>E</bold>) Immunofluorescence staining for pituitary stem cell markers SOX2 and SOX9 reveal that tumour lesions have abundant positive cells compared to the control, while Endomucin (EMCN) staining shows poor vascularisation. (<bold>F</bold>) The marginal zone epithelium of <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> mutant pituitaries develops invaginations as seen by haematoxylin and eosin staining. Immunofluorescence staining against SOX2 shows the maintenance of a single-layered epithelium. Scale bars 100 µm. Boxes indicate magnified regions. See also <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43996-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.43996.010</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Analysis of tumourigenic lesions in postnatal pituitaries following pituitary-specific deletion of <italic>Lats1.</italic></title><p>(<bold>A</bold>) Immunofluorescence staining for TAZ and active YAP reveal lesions of accumulation at P21 in <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic>compared to <italic>Hesx1<sup>+/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic>control. Immunofluorescence staining using antibodies against SOX2 and Endomucin (EMCN) show these lesions are composed of SOX2+ stem cells and have reduced vascularisation. (<bold>B</bold>) Hematoxylin and eosin staining of frontal sections from <italic>Hesx1<sup>Cre/+</sup>;Lats2<sup>fl/fl</sup></italic> and <italic>Hesx1<sup>Cre/+</sup></italic> control pituitaries at P56 showing comparable histology. (<bold>C</bold>) Immunofluorescence staining against SOX2 and Endomucin on an intermediate lobe lesion (asterisk) in a <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> pituitary compared to control. (<bold>D</bold>) Immunofluorescence staining against DNA damage marker gamma H2A.X showing positive cells in <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+ </sup></italic>mutants. (<bold>E</bold>) P56 Immunohistochemistry using antibodies against p63 and the AE1/AE3 cytokeratin cocktail, both positive in pituitary carcinomas, showing abundant staining in <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> compared to control. Note that membrane staining detected in controls is background for both antibodies. (<bold>F</bold>) Immunohistochemistry using antibodies against synaptophysin, neural-specific enolase (NSE) and chromogranin demonstrate negative immunoreactivity in tumourigenic lesions of <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> pituitaries. Lesions are also negative for vimentin by immunofluorescence staining. Scale bars 100 µm in A, C-F; 500 µm in B. PL: posterior lobe, IL: intermediate lobe, AL: anterior lobe.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43996-fig3-figsupp1-v2.tif"/></fig></fig-group><p>In keeping with the morphological evidence of epithelial differentiation (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), the tumours were positive for cytokeratins using AE1/AE3 (multiple keratin cocktail) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). Furthermore, the tumours showed focal morphological evidence of squamous differentiation and showed positive nuclear p63 staining, frequently expressed in squamous carcinomas (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). In contrast, the tumours did not show immunohistochemical evidence of adenomas, that is, they were negative for neuroendocrine markers, which all types of adenomas are typically positive for: the neuroendocrine marker synaptophysin and neuron-specific enolase (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>). The lesions were also negative for chromogranin A, a neuroendocrine granule marker often expressed in clinically non-functioning pituitary adenomas. Tumours were also negative for vimentin, expressed by spindle cell oncocytoma, an uncommitted posterior pituitary tumour (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>). Moreover, immunostaining against PIT1, TPIT and SF1 showed only sparse positive cells within the lesions, suggesting lack of commitment into endocrine precursors and supporting the undifferentiated nature of the tumour cells (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Consistent with a tumourigenic phenotype, and role for LATS1 genomic stabilisation (<xref ref-type="bibr" rid="bib41">Pefani et al., 2014</xref>), staining for gamma-H2A.X detected elevated DNA damage in cells of the mutant pituitaries compared with controls (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). The absence of adenoma or oncocytoma markers together with the histological appearance, observation of focal necrosis and a high mitotic index support the features of squamous carcinoma.</p></sec><sec id="s2-4"><title>SOX2+ cells are the cell of origin of the tumours</title><p>Tumour regions were mostly composed of SOX2 positive cells, a sub-population of which also expressed SOX9 (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>; 85–97% of cells, 7 tumours across four pituitaries). Close examination of the marginal zone epithelium, a major SOX2+ stem cell niche of the pituitary, revealed a frequent ‘ruffling’ resembling crypts, likely generated through over-proliferation of the epithelial stem cell compartment (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). To determine if the cell of origin of the tumourigenic lesions is a deregulated SOX2+ stem cell, we carried our specific deletion of LATS1/2 in postnatal SOX2+ cells using the tamoxifen-inducible <italic>Sox2-CreERT2</italic> driver, combined with conditional expression of membrane-GFP in targeted cells (<italic>Sox2<sup>CreERT2/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup>;R26<sup>mTmG/+</sup></italic>).</p><p>Tamoxifen induction at P5 or P21, led to abnormal lesions in the anterior pituitary within three months in all cases. We focused our analyses on inductions performed at P5, from which time point all animals developed lesions by P35 (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Similar to observations in <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> animals, these areas strongly accumulated YAP and TAZ (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), activated expression of targets <italic>Cyr61</italic> and <italic>Ctgf</italic>, displayed ruffling of the AL epithelium (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>) and lacked lineage commitment markers (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). These lesions showed a similar marker profile to <italic>Hesx1-Cre</italic>-targeted tumours, with positive p63 and AE1/AE3 staining (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). Lineage tracing confirmed expression of membrane GFP in tumourigenic lesions, characterised by the accumulation of YAP and expansion of SOX2+ cells, suggesting they were solely derived from SOX2+ cells (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). Taken together, our data support that LATS kinase activity is required to regulate the pituitary stem cell compartment. Loss of LATS1 is sufficient to drive deregulation of SOX2+ pituitary stem cells, generating highly proliferative non-functioning tumours with features of carcinomas.</p><fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.43996.011</object-id><label>Figure 4.</label><caption><title>SOX2+ pituitary stem cells are the cell-of-origin of tumours generated in the absence of <italic>Lats1</italic>.</title><p>(<bold>A</bold>) Schematic outlining the experimental time line of inductions in <italic>Sox2<sup>CreERT2/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> (mutant) and <italic>Sox2<sup>+/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> (control) animals. Representative images of haematoxylin and eosin staining of frontal sections of control and mutant pituitaries at P35, revealing a hyperplastic anterior pituitary in the mutant with areas of necrosis (asterisks). (<bold>B</bold>) Immunofluorescence staining reveals tumourigenic lesions in <italic>Sox2<sup>CreERT2/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> that display increased levels of TAZ and YAP staining compared to the control. (<bold>C</bold>) RNAscope mRNA in situ hybridisation against <italic>Ctgf</italic> and <italic>Cyr61</italic> shows elevated transcripts in tumourigenic lesions. Insets (<bold>i</bold>) and (ii) show invaginations in the epithelium of the mutant. (<bold>D</bold>) Immunofluorescence staining for lineage-committed progenitor markers PIT1, TPIT and SF1 showing a reduction in staining in tumourigenic lesions compared to control pituitaries. (<bold>E</bold>) Lineage tracing of SOX2+ cells in <italic>Sox2<sup>CreERT2/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup>R26<sup>mTmG/+</sup></italic> reveals that tumour regions accumulating YAP as seen by immunofluorescence, are composed of GFP+ cells at P35. Scale bars 500 µm in A; 100 µm in B, D, E; 250 µm in C. See also <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43996-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.43996.012</object-id><label>Figure 4—figure supplement 1.</label><caption><title>Analysis of tumourigenic lesions in postnatal pituitaries following SOX2-specific deletion of <italic>Lats1.</italic></title><p>(<bold>A</bold>) Graph of quantification of lineage commitment markers PIT1, TPIT and SF1, as a percentage of all anterior pituitary cells, in <italic>Sox2<sup>+/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> (control) and <italic>Sox2<sup>CreERT2/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> (mutant) pituitaries. There is a significant reduction in the percentage of committed cells of all three lineages in mutants compared to controls (Student’s <italic>t</italic>-test; PIT1: p&lt;0.0001 (****), TPIT: p&lt;0.0001 (****), SF1: p=0.004 (**)). (<bold>B</bold>) Immunohistochemistry using specific antibodies against p63 and cytokeratin cocktail AE1/AE3 on frontal sections of <italic>Sox2<sup>CreERT2/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> (mutant) and <italic>Sox2<sup>+/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> (control) pituitaries at P35, revealing positive staining in mutants. Note that the membrane staining in controls is background for both antibodies. (<bold>C</bold>) Double immunofluorescence staining against total YAP and GFP, as well as SOX2 and GFP in consecutive sections of a tumourigenic lesion from <italic>Sox2<sup>CreERT2/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic>;R26<italic><sup>mTmG/+</sup></italic> pituitaries at P35. Lineage tracing of SOX2+ cells, detected using GFP reveals abundant staining in the tumour lesion, characterised by accumulation of YAP and SOX2+ cells (yellow arrowheads). Scale bars 100 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43996-fig4-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-5"><title>YAP expression is sufficient to activate pituitary stem cells</title><p>Conditional deletion of LATS1/2 kinases in the pituitary has revealed how these promote an expansion of SOX2+ stem cells in the embryonic and postnatal gland at the expense of differentiation. To establish if this effect was mediated through YAP alone, we used the tetracycline-controlled conditional YAP-TetO system to promote YAP (S127A) protein levels in postnatal pituitaries of <italic>Hesx1<sup>Cre/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> mice. We treated YAP-TetO animals with doxycycline from P21 to P105 (12 week treatment, <xref ref-type="fig" rid="fig5">Figure 5A</xref>). We did not observe the formation of tumours at any stage analysed (n = 12, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Similarly, we did not observe the formation of lesions when treating from P5. This is in contrast with the unequivocal tumour formation observed in <italic>Sox2<sup>CreERT2/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> mice. Elevation of YAP protein levels was confirmed following three weeks of doxycycline treatment (P42), displaying patchy accumulation, likely a result of genetic recombination efficiencies (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Consistent with pathway activation, there was robust elevation in the expression of transcriptional targets <italic>Cyr61</italic> and <italic>Ctgf</italic> following treatment (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>), however at significantly lower levels compared to <italic>Sox2<sup>CreERT2/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> deletions (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>), and there was no elevation in phosphorylated inactive YAP (<xref ref-type="fig" rid="fig5">Figure 5B</xref>).</p><fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.43996.013</object-id><label>Figure 5.</label><caption><title>Postnatal expression of constitutively active YAP increases leads to an activation of SOX2+ pituitary stem cells.</title><p>(<bold>A</bold>) Schematic outlining the time course of doxycycline (DOX) treatment administered to <italic>Hesx1<sup>Cre/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> (YAP-TetO) and <italic>Hesx1<sup>+/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> controls to drive expression of YAP-S127A in mutant pituitaries. (<bold>B</bold>) At P42 (3 weeks of treatment), immunofluorescence staining on frontal anterior pituitary sections detects strong total YAP expression in YAP-TetO mutants compared to the control and no increase in pYAP(S127). Immunofluorescence for SOX2 and SOX9 reveals an expanded population of stem cells in YAP-TetO compared to control (quantification in F). (<bold>C</bold>) Graph showing the percentage of double Ki-67+;SOX2+ cells as a proportion of the total SOX2+ (p<italic>=</italic>0.027 (*)) or Ki-67+ (p<italic>=</italic>0.006 (**)) populations at P42 (n = 3 pituitaries per genotype). There is an increase in the numbers of cycling SOX2 cells in YAP-TetO mutant compared to controls. The image shows a representative example of double immunofluorescence staining against Ki-67 and SOX2 in a control and YAP-TetO section. (<bold>D</bold>) Schematic outlining the time course of doxycycline (DOX) treatment administered to <italic>Hesx1<sup>Cre/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> (YAP-TetO) and <italic>Hesx1<sup>+/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> controls to drive expression of YAP-S127A in mutant pituitaries for three weeks, followed by a three-week recovery period in the absence of DOX. (<bold>E</bold>) Immunofluorescence staining against YAP, SOX2 and SOX9 on control and YAP-TetO pituitaries treated as in D, shows comparable expression of YAP, SOX2 and SOX9 between genotypes. (<bold>F</bold>) Graph of quantification of SOX2+ cells as a percentage of total nuclei in control and YAP-TetO pituitaries at P42 p<italic>=</italic>0.0014 (**); P63 p<italic>=</italic>0.0044 (**); P105 p<italic>&lt;</italic>0.0001(****) (n = 3 pituitaries per genotype). Following the Recovery treatment scheme in D, there is no significant difference in the numbers of SOX2+ cells between genotypes. (<bold>G</bold>) Schematic outlining the time course of tamoxifen induction and doxycycline (DOX) treatment administered to <italic>Sox2<sup>CreERT2/+</sup>;R26<sup>rtTA/mTmG</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> (mutant) and <italic>Sox2<sup>CreERT2/+</sup>;R26<sup>mTmG/+</sup>;Col1a1<sup>+/+</sup></italic> (control) animals to drive expression of YAP-S127A in SOX2+ cells of mutants. (<bold>H</bold>) Lineage tracing of SOX2+ cells and immunofluorescence staining against SOX2 and GFP shows an expansion of GFP+ cells compared to controls at P63, where a proportion of cells are double-labelled. (<bold>I</bold>) Immunofluorescence staining against commitment markers PIT1, SF1 and terminal differentiation marker ACTH (TPIT lineage) together with antibodies against GFP detects double-labelled cells (arrows) across all three lineages in <italic>Sox2<sup>CreERT2/+</sup>;R26<sup>rtTA/mTmG</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> pituitaries following the recovery period. Graph of quantification of GFP+;PIT1+, GFP+;SF1+ and GFP+;ACTH+ cells as a percentage of total GFP+ cells in <italic>Sox2<sup>CreERT2/+</sup>;R26<sup>rtTA/mTmG</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> pituitaries at P63. Scale bars 100 µm. Data in C. and F. represented as mean ±SEM, analysed with Two-Way ANOVA with Sidak’s multiple comparisons. See also <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43996-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.43996.014</object-id><label>Figure 5—figure supplement 1.</label><caption><title>Postnatal expression of constitutively active YAP leads to an activation of SOX2+ pituitary stem cells.</title><p>(<bold>A</bold>) Schematic outlining the time course of doxycycline (DOX) treatment administered to <italic>Hesx1<sup>Cre/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> (YAP-TetO) and <italic>Hesx1<sup>+/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> controls to drive expression of YAP-S127A in mutant pituitaries. Hematoxylin and eosin staining of control and YAP-TetO pituitaries at P42 (3 weeks treatment), P63 (6 weeks treatment) and P105 (12 weeks treatment). (<bold>B</bold>) RNAscope mRNA in situ hybridisation against YAP targets <italic>Cyr61</italic> and <italic>Ctgf</italic> showing increased transcripts in YAP-TetO sections compared to controls at P42. (<bold>C</bold>) Analysis of YAP-TetO mutants at P105: double immunofluorescence staining against SOX2 and Ki-67 reveals regions of expanded SOX2+;Ki-67- cells compared to the normal expression pattern in the control. This region is SOX9+, does not accumulate TAZ or YAP and expresses pYAP as does normal anterior pituitary epithelium. Immunofluorescence against PIT1 shows the absence of commitment to this lineage, a pattern not seen in the control. Hematoxylin and eosin staining in consecutive sections identifies this region, which does not have neoplastic features. (<bold>D</bold>) Schematic outlining the time course of doxycycline (DOX) treatment administered to <italic>Hesx1<sup>Cre/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> (YAP-TetO) and <italic>Hesx1<sup>+/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> controls to drive expression of YAP-S127A in mutant pituitaries for three weeks, followed by a three-week recovery period in the absence of DOX. Hematoxylin and eosin staining of control and YAP-TetO pituitaries. RNAscope mRNA in situ hybridisation shows comparable levels of expression of targets <italic>Cyr61</italic> and <italic>Ctgf.</italic> <bold>E</bold>) Graph comparing total fluorescence of <italic>Cyr61</italic> and <italic>Ctgf</italic> by Fast Red RNAscope mRNA in situ hybridisation across sections from control, <italic>Hesx1<sup>Cre/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> (YAP-TetO) and <italic>Sox2<sup>CreERT2/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> anterior pituitaries, normalised for total anterior pituitary area. There is a significant increase in the expression of both targets in <italic>Sox2<sup>CreERT2/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> pituitaries compared to other genotypes (one-way ANOVA with Tukey’s post hoc test; Control v <italic>Sox2<sup>CreERT2/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup>: p</italic>&lt;0.0001 for <italic>Cyr61</italic> (****), p=0.001 for <italic>Ctgf</italic> (***); YAP-TetO v <italic>Sox2<sup>CreERT2/+</sup>;Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup>: p</italic>&lt;0.0001 for <italic>Cyr61</italic> (****), p=0.0049 for <italic>Ctgf</italic> (**)). Scale bars 250 µm in A, 100 µm in B-D.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43996-fig5-figsupp1-v2.tif"/></fig></fig-group><p>Immunofluorescence against SOX2 demonstrated a significant increase in the number of SOX2+ cells as a proportion of the anterior pituitary (<xref ref-type="fig" rid="fig5">Figure 5B,F</xref>; 18.0% compared to 12.1% in controls, p=0.0014), a finding recapitulated by SOX9 that marks a subset of the SOX2 population (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). This increase in the percentage of SOX2+ cells was maintained at all stages analysed (<xref ref-type="fig" rid="fig5">Figure 5F</xref>) and did not affect the overall morphology of the pituitary. At P42 we observed a significant increase in proliferation among the SOX2+ pituitary stem cells from 3% in controls to 15% in mutants (p=0.027). SOX2+ cells make up 10% of all cycling cells (Ki-67%) in normal pituitaries, however in mutants this increased to 25%, suggesting a preferential expansion of the SOX2+ population, rather than an overall increase in proliferation (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). No additional marked differences were observed in samples analysed at P63 (6 weeks of treatment, n = 3), however longer treatment (P21 to P105) resulted in sporadic regions of expanded SOX2+ cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>). These regions did not express the commitment marker PIT1 and were identifiable by haematoxylin/eosin staining. In contrast to tumour lesions generated following loss of LATS kinases, these were not proliferative, were positive for pYAP and did not accumulate high levels of YAP/TAZ (n = 6 lesions). Together these results suggest that the sustained expression of constitutive active YAP can activate the proliferation of SOX2 stem cells, but in contrast to deletion of LATS1, this alone is not oncogenic.</p><p>To establish if the expansion of pituitary stem cells following forced expression of YAP is reversible, we administered doxycycline to YAP-TetO animals for three weeks (P21 to P42) by which point there is a robust response, followed by doxycycline withdrawal for three weeks (until P63) to allow sufficient time for YAP levels to return to normal (scheme <xref ref-type="fig" rid="fig5">Figure 5D</xref>). Immunofluorescence against total YAP protein confirmed restoration of the normal YAP expression pattern and levels after recovery (<xref ref-type="fig" rid="fig5">Figure 5E</xref>), and mRNA in situ hybridisation detected a reduction in expression of YAP/TAZ targets <italic>Cyr61</italic> and <italic>Ctgf</italic> (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). Following recovery from high levels of YAP, the number of SOX2+ cells reduced to comparable levels as in controls (around 10% of the total anterior pituitary) (<xref ref-type="fig" rid="fig5">Figure 5E,F</xref>). This suggests that the effects of YAP overexpression on the stem cell population are transient following three weeks of treatment (<xref ref-type="fig" rid="fig5">Figure 5F</xref>).</p><p>Finally, to determine if SOX2+ cells could differentiate into hormone-producing cells after the reduction in YAP levels, we expressed constitutive active YAP only in SOX2+ cells while lineage tracing this population (<italic>Sox2<sup>CreERT2/+</sup>;R26<sup>rtTA/mTmG</sup>;Col1a1<sup>tetO-Yap/+</sup></italic>). We induced SOX2+ cells by low-dose tamoxifen administration at P21 and treated with doxycycline for three weeks, followed by doxycycline withdrawal for a further three weeks (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Larger clones of SOX2 derivatives were observed at P63 in <italic>Sox2<sup>CreERT2/+</sup>;R26<sup>rtTA/mTmG</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> animals compared to controls, and these still contained SOX2+ cells (<xref ref-type="fig" rid="fig5">Figure 5H</xref>). Following withdrawal, we were able to detect GFP+ derivatives of SOX2+ cells, which had differentiated into the three lineages (PIT1, SF1 and ACTH, marking corticotrophs of the TPIT lineage) (<xref ref-type="fig" rid="fig5">Figure 5I</xref>). Taken together, these findings confirm that sustained expression of YAP is sufficient to maintain the SOX2+ state and promote activation of normal SOX2+ pituitary stem cells in vivo, driving expansion of this population.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Here we establish that regulation of LATS/YAP/TAZ signalling is essential during anterior pituitary development and can influence the activity of the stem/progenitor cell pool. LATS kinases, mediated by YAP and TAZ, are responsible for controlling organ growth, promoting an undifferentiated state and repressing lineage commitment. Loss of both <italic>Lats1</italic> and <italic>Lats2</italic>, encoding potent tumour suppressors, leads to dramatic tissue overgrowth during gestation, revealing a function for these enzymes in restricting growth during pituitary development. The involvement of YAP/TAZ and dysfunction of the kinase cascade is emerging in multiple paediatric cancers, which are often developmental disorders (<xref ref-type="bibr" rid="bib1">Ahmed et al., 2017</xref>).</p><p>Loss of <italic>LATS1</italic> heterozygosity has been reported in a range of human tumours (<xref ref-type="bibr" rid="bib23">Lee et al., 1990</xref>; <xref ref-type="bibr" rid="bib9">Chen et al., 2005</xref>; <xref ref-type="bibr" rid="bib51">Theile et al., 1996</xref>; <xref ref-type="bibr" rid="bib31">Mazurenko et al., 1999</xref>) leading to an increase in YAP/TAZ protein levels. Previous global deletion of <italic>Lats1</italic> in mice resulted in a variety of soft tissue sarcomas and stromal cell tumours (<xref ref-type="bibr" rid="bib50">St John et al., 1999</xref>). The anterior lobe of these animals appeared hyperplastic with poor endocrine cell differentiation leading to combined hormone deficiencies, but the presence of tumours was not noted. We report that loss of <italic>Lats1</italic> alone is sufficient to drive anterior and intermediate lobe tumour formation. This phenotype is accelerated following additional deletion of one copy of <italic>Lats2</italic>. Phenotypically identical tumour lesions were generated when the genetic deletions were carried out embryonically in RP, or at postnatal stages. Interestingly, tissue-specific loss of <italic>Stk3</italic> and <italic>Stk4</italic>, which regulate LATS activation in other tissues (<xref ref-type="bibr" rid="bib18">Hu et al., 2017</xref>), did not lead to any pituitary defects despite reduction in STK3/4 levels. These data suggest that perhaps the residual activity of STK3/4 is sufficient for LATS1/2 activation. Alternatively, regulation of LATS1/2 by kinases other than STK3/4 is possible in the pituitary, meaning deletion of <italic>Stk3/4</italic> alone is insufficient to result in significant LATS function impairment. Similar situations have been reported in other organs where LATS are functioning (<xref ref-type="bibr" rid="bib18">Hu et al., 2017</xref>). The resulting non-secreting tumours in our mouse models are composed predominantly of SOX2+ stem cells and display signs of squamous differentiation. Rare cases of squamous cell carcinoma have been reported as primary pituitary tumours (<xref ref-type="bibr" rid="bib45">Saeger et al., 2007</xref>), but more frequently, arising within cysts that are normally non-neoplastic epithelial malformations (<xref ref-type="bibr" rid="bib25">Lewis et al., 1983</xref>; <xref ref-type="bibr" rid="bib38">O'Neill et al., 2016</xref>). In the embryonic YAP-TetO model, where constitutive active YAP (S127A) was expressed during pituitary development, cysts phenocopying Rathke’s cleft cyst, develop by postnatal stages. Target elevation is not as high in YAP-TetO pituitaries, as following the deletion of LATS1/2, indicating that signalling levels are likely to be critical for progression between these phenotypes.</p><p>Although human pituitary carcinomas are only diagnosed as such after metastasis, the tumours generated in our LATS1/2 mouse models fit their histopathological profile. Genetic lineage tracing identified SOX2+ cells as the cell of origin of the tumours; this observation could have ramifications regarding involvement of the LATS/YAP/TAZ pathway in the establishment or progression of human pituitary tumours composed of uncommitted cells. In cancer stem cells of osteosarcoma and glioblastoma, SOX2 antagonises upstream Hippo activators, leading to enhanced YAP function (<xref ref-type="bibr" rid="bib5">Basu-Roy et al., 2015</xref>). We recently reported enhanced expression of YAP/TAZ in a range of non-functioning human pituitary tumours, compared to functioning adenomas, and that <italic>Lats1</italic> knock-down in GH3 pituitary mammosomatotropinoma cells results in repression of the <italic>Gh</italic> and <italic>Prl</italic> promoters (<xref ref-type="bibr" rid="bib55">Xekouki et al., 2019</xref>). Therefore, YAP/TAZ, perhaps in a positive feedback loop with SOX2, are likely to function both to promote the maintenance of an active pituitary stem cell state as well as to inhibit differentiation.</p><p>By dissecting the downstream requirement for YAP in pituitary regulation by the LATS/YAP/TAZ axis, we found that expression of constitutively active YAP (S127A) is sufficient to push SOX2+ pituitary stem cells into an activated state, leading to expansion of the stem cell cohort (see Model, <xref ref-type="fig" rid="fig6">Figure 6</xref>). YAP has previously been indicated to promote the stem cell state in other tissues, for example pancreas, neurons and mammary glands (<xref ref-type="bibr" rid="bib39">Panciera et al., 2016</xref>). However, this does not fully recapitulate the LATS deletion phenotypes, as it did not lead to the formation of tumours during the time course of YAP activation (12 weeks). Interestingly, since the levels of target activation are significantly greater in <italic>Lats1/2</italic> deletions that in YAP-TetO activation, initiation of tumourigenesis may be associated with levels of signalling rising above a threshold. However, the temporal control of expressing the mutation is critical, as seen in other tumour models (<xref ref-type="bibr" rid="bib15">Han et al., 2016</xref>). Instead, the findings identify an isolated role for YAP in promoting the expansion of the SOX2+ stem cell pool and restoring their proliferative potential to levels akin to the most active state during postnatal pituitary growth. Activity of YAP/TAZ is reduced in dense tissues, resulting in a decrease in stemness. One mechanism through which this is achieved is by crosstalk with other signalling pathways regulating stem cell fate (<xref ref-type="bibr" rid="bib40">Papaspyropoulos et al., 2018</xref>; <xref ref-type="bibr" rid="bib16">Heallen et al., 2011</xref>). For example, a decrease in YAP/TAZ activity removes inhibition on Notch signalling, resulting in higher levels of differentiation and a drop in stem cell potential (<xref ref-type="bibr" rid="bib53">Totaro et al., 2017</xref>). In the pituitary, Notch plays a role in the maintenance of the SOX2 stem cell compartment and is involved in regulating differentiation (<xref ref-type="bibr" rid="bib62">Zhu et al., 2015</xref>; <xref ref-type="bibr" rid="bib35">Nantie et al., 2014</xref>; <xref ref-type="bibr" rid="bib10">Cheung et al., 2013</xref>; <xref ref-type="bibr" rid="bib6">Batchuluun et al., 2017</xref>). The downstream mechanisms of YAP action on SOX2+ pituitary stem cells, as well as the likely crosstalk with other signalling pathways remain to be explored.</p><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.43996.015</object-id><label>Figure 6.</label><caption><title>Model of stem cell activity following regulation by the LATS/YAP/TAZ cascade in the anterior pituitary.</title><p>SOX2+ pituitary stem cells express YAP and TAZ (green spheres). During normal developmental and postnatal expansion (normal regulation), pituitary stem cells are maintained as a balanced pool while generating endocrine cells of three committed lineages (red, blue, yellow). Expression of constitutively active YAP-S127A in pituitary stem cells leads to an elevation in target gene expression, an expansion of pituitary stem cell numbers and maintenance of the SOX2+ state, preventing lineage commitment. When YAP-S127A expression ceases, commitment into the endocrine lineages takes place. Genetic deletion of LATS kinases (LATS1 as well as one or two copies of LATS2), results in YAP and TAZ accumulation, major elevation in target gene expression, repression of lineage commitment, continued expansion of SOX2+ cells and tumour formation.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-43996-fig6-v2.tif"/></fig><p>In summary, our findings highlight roles for LATS/YAP/TAZ in the regulation of pituitary stem cells, where fine-tuning of their expression can make the difference between physiological stem cell re-activation and tumourigenesis, of relevance to other organs. We reveal this axis is involved in the control of cell fate commitment, regulation of regenerative potential and promotion of tumourigenesis. These findings can aid in the design of treatments against pituitary tumours and in regenerative medicine approaches targeting the regulation of endogenous stem cells.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or <break/>resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional <break/>information</th></tr></thead><tbody><tr><td valign="top">Genetic reagent <break/>(<italic>M. musculus</italic>)</td><td valign="top"><italic>Hesx1<sup>Cre/+</sup></italic></td><td valign="top"><xref ref-type="bibr" rid="bib2">Andoniadou et al., 2007</xref></td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/MGI:5314529">MGI:5314529</ext-link></td><td valign="top"/></tr><tr><td valign="top">Genetic reagent <break/>(<italic>M. musculus</italic>)</td><td valign="top"><italic>Sox2<sup>CreERT2/+</sup></italic></td><td valign="top"><xref ref-type="bibr" rid="bib4">Andoniadou et al., 2013</xref></td><td valign="top">MGI:5512893</td><td valign="top"/></tr><tr><td valign="top">Genetic reagent <break/>(<italic>M. musculus</italic>)</td><td valign="top"><italic>Lats1<sup>fl/fl</sup></italic></td><td valign="top">Jackson Laboratory</td><td valign="top">Stock #: 024941, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/MGI:5568576">MGI:5568576</ext-link></td><td valign="top"/></tr><tr><td valign="top">Genetic reagent <break/>(<italic>M. musculus</italic>)</td><td valign="top"><italic>Lats2<sup>fl/fl</sup></italic></td><td valign="top">Jackson Laboratory</td><td valign="top">Stock #: 025428, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/MGI:5568577">MGI:5568577</ext-link></td><td valign="top"/></tr><tr><td valign="top">Genetic reagent <break/>(<italic>M. musculus</italic>)</td><td valign="top"><italic>Stk4<sup>fl/fl</sup>;Stk3<sup>fl/fl</sup></italic></td><td valign="top">Jackson Laboratory</td><td valign="top">Stock #: 017635, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/MGI:5301573">MGI:5301573</ext-link></td><td valign="top"><xref ref-type="bibr" rid="bib29">Lu et al., 2010</xref></td></tr><tr><td valign="top">Genetic reagent <break/>(<italic>M. musculus</italic>)</td><td valign="top">R26<sup>rtTA/+</sup></td><td valign="top">Jackson Laboratory</td><td valign="top">Stock: #: 016999 <break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/MGI:5292520">MGI:5292520</ext-link></td><td valign="top"><xref ref-type="bibr" rid="bib56">Yu et al., 2005</xref></td></tr><tr><td valign="top">Genetic reagent <break/>(<italic>M. musculus</italic>)</td><td valign="top"><italic>Col1a1<sup>tetO-Yap/+</sup></italic></td><td valign="top"><xref ref-type="bibr" rid="bib20">Jansson and Larsson, 2012</xref></td><td valign="top">MGI:5430522</td><td valign="top"/></tr><tr><td valign="top">Genetic reagent <break/>(<italic>M. musculus</italic>)</td><td valign="top"><italic>R26<sup>mTmG/+</sup></italic></td><td valign="top">JacksonLaboratory</td><td valign="top">Stock #: 007576 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/MGI:3722405">MGI:3722405</ext-link></td><td valign="top"><xref ref-type="bibr" rid="bib34">Muzumdar et al., 2007</xref></td></tr><tr><td valign="top">Genetic reagent <break/>(<italic>M. musculus</italic>)</td><td valign="top"><italic>Taz<sup>-/-</sup></italic></td><td valign="top">Jackson Laboratory</td><td valign="top">Stock #: 011120, RRID: <ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/MGI:4420900">MGI:4420900</ext-link></td><td valign="top"><xref ref-type="bibr" rid="bib52">Tian et al., 2007</xref></td></tr><tr><td valign="top">Genetic reagent <break/>(<italic>M. musculus</italic>)</td><td valign="top"><italic>Yap<sup>fl/fl</sup></italic></td><td valign="top"><xref ref-type="bibr" rid="bib48">Schlegelmilch et al., 2011</xref></td><td valign="top">MGI:5316446</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit polyclonal anti-TAZ</td><td valign="top">Atlas Antibodies</td><td valign="top">Cat# HPA007415 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1080602">AB_1080602</ext-link></td><td valign="top">IF: 1:1000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit polyclonal anti-YAP</td><td valign="top">Cell Signaling <break/>Technology</td><td valign="top">Cat# 4912S <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2218911">AB_2218911</ext-link></td><td valign="top">IF: 1:1000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit polyclonal anti-pYAP</td><td valign="top">Cell Signaling <break/>Technology</td><td valign="top">Cat# 4911S <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2218913">AB_2218913</ext-link></td><td valign="top">IF: 1:1000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit polyclonal <break/>anti-SOX2</td><td valign="top">Abcam</td><td valign="top">Cat# ab97959 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2341193">AB_2341193</ext-link></td><td valign="top">IF: 1:2000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rat monoclonal <break/>anti-EMCN <break/>(V.7C7.1)</td><td valign="top">Abcam</td><td valign="top">Cat# ab106100 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10859306">AB_10859306</ext-link></td><td valign="top">IF: 1:1000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Chicken polyclonal anti-GFP</td><td valign="top">Abcam</td><td valign="top">Cat# ab13970 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_300798">AB_300798</ext-link></td><td valign="top">IF: 1:300</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat <break/>polyclonal anti- <break/>SOX2</td><td valign="top">Immune Systems <break/>Limited</td><td valign="top">Cat# GT15098 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2732043">AB_2732043</ext-link></td><td valign="top">IF: 1:250</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit monoclonal anti-Ki-67</td><td valign="top">Abcam</td><td valign="top">Cat# ab16667 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_302459">AB_302459</ext-link></td><td valign="top">IF: 1:300</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit <break/>polyclonal anti- <break/>ARL13B</td><td valign="top">Proteintech <break/>Group</td><td valign="top">Cat# 17711–1-AP, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2060867">AB_2060867</ext-link></td><td valign="top">IF: 1:100</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse monoclonal anti-Acetylated-αTUB</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# MABT868</td><td valign="top">IF: 1:200</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit monoclonal anti-SOX9</td><td valign="top">Abcam</td><td valign="top">Cat# ab185230 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2715497">AB_2715497</ext-link></td><td valign="top">IF: 1:300</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit monoclonal <break/>anti-Active YAP <break/>EPR19812</td><td valign="top">Abcam</td><td valign="top">Cat# ab205270</td><td valign="top">IF: 1:300</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit <break/>polyclonal anti- <break/>PIT1</td><td valign="top">Prof. S Rhodes <break/>(Indiana University)</td><td valign="top"/><td valign="top">IF: 1:1000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit <break/>polyclonal anti- <break/>TPIT</td><td valign="top">Prof. J Drouin <break/>(Montreal IRCM)</td><td valign="top"/><td valign="top">IF: 1:1000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse monoclonal <break/>anti-SF1</td><td valign="top">Life Technologies <break/>(Thermo Fisher <break/>Scientific)</td><td valign="top">Cat# N1665 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2532209">AB_2532209</ext-link></td><td valign="top">IF: 1:200</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit polyclonal anti- <break/>gamma H2A.X <break/>(phospho S139)</td><td valign="top">Abcam</td><td valign="top">Cat# ab2893 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_303388">AB_303388</ext-link></td><td valign="top">IF: 1:1000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit <break/>polyclonal anti- <break/>STK3/4</td><td valign="top">Bethyl Laboratories</td><td valign="top">Cat# A300-466A <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2148394">AB_2148394</ext-link></td><td valign="top">WB: 1:5000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse monoclonal anti-Cyclophilin B <break/>(Clone# 549205)</td><td valign="top">R and D Systems</td><td valign="top">Cat# MAB5410 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2169416">AB_2169416</ext-link></td><td valign="top">WB: 1:1000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit monoclonal <break/>anti-Vimentin <break/>(D21H3)</td><td valign="top">Cell Signaling <break/>Technology</td><td valign="top">Cat# 5741 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10695459">AB_10695459</ext-link></td><td valign="top">IF: 1:300</td></tr><tr><td valign="top">Antibody</td><td valign="top">Biotinylated Goat <break/>polyclonal anti- <break/>rabbit</td><td valign="top">Abcam</td><td valign="top">Cat# ab6720 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_954902">AB_954902</ext-link></td><td valign="top">IF: 1:350</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat polyclonal anti-chicken <break/>Alexa Fluor 488</td><td valign="top">Life Technologies <break/>(Thermo Fisher <break/>Scientific)</td><td valign="top">Cat# A11039 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2534096">AB_2534096</ext-link></td><td valign="top">IF: 1:300</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat polyclonal anti-rat Alexa Fluor 555</td><td valign="top">Life Technologies <break/>(Thermo Fisher Scientific)</td><td valign="top">Cat# A21434 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2535855">AB_2535855</ext-link></td><td valign="top">IF: 1:300</td></tr><tr><td valign="top">Antibody</td><td valign="top">Biotinylated Goat polyclonal anti-mouse</td><td valign="top">Abcam</td><td valign="top">Cat# ab6788 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_954885">AB_954885</ext-link></td><td valign="top">IF: 1:350</td></tr><tr><td valign="top">Antibody</td><td valign="top">Donkey polyclonal anti-goat Alexa Fluor 488</td><td valign="top">Abcam</td><td valign="top">Cat# ab150133</td><td valign="top">IF: 1:300</td></tr><tr><td valign="top">Antibody</td><td valign="top">Streptavidin Alexa Fluor 555</td><td valign="top">Life Technologies</td><td valign="top">Cat# S21381 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2307336">AB_2307336</ext-link></td><td valign="top">IF: 1:500</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat HRP-linked anti-rabbit</td><td valign="top">Cell Signaling Technology</td><td valign="top">Cat# 7074 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2099233">AB_2099233</ext-link></td><td valign="top">WB: 1:2000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat HRP-linked anti-mouse</td><td valign="top">Cell Signaling Technology</td><td valign="top">Cat# 7076 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_330924">AB_330924</ext-link></td><td valign="top">WB: 1:2000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse monoclonal anti-AE1/AE3</td><td valign="top">Dako</td><td valign="top">Cat# M351529</td><td valign="top">IHC: 1:100</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse monoclonal anti-Chromogranin</td><td valign="top">Dako</td><td valign="top">Cat# M086901</td><td valign="top">IHC: 1:400</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse monoclonal anti-NCAM</td><td valign="top">Novocastra</td><td valign="top">Cat# NCL-L-CD56-504</td><td valign="top">IHC 1:15</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse monoclonal anti-NSE</td><td valign="top">Dako</td><td valign="top">Cat# M087329</td><td valign="top">IHC 1:1000</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse monoclonal anti-p63</td><td valign="top">A Menarini <break/>Diagnostics</td><td valign="top">Cat# MP163</td><td valign="top">IHC 1:100</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse monoclonal anti-Synaptophysin</td><td valign="top">Dako</td><td valign="top">Cat# M731529 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2687942">AB_2687942</ext-link></td><td valign="top">IHC 1:2</td></tr><tr><td valign="top">Commercial <break/>assay or kit</td><td valign="top">TSA kit</td><td valign="top">Perkin Elmer</td><td valign="top">Cat# NEL753001KT</td><td valign="top"/></tr><tr><td valign="top">Commercial <break/>assay or kit</td><td valign="top">TSA Blocking Reagent</td><td valign="top">Perkin Elmer</td><td valign="top">Cat# FP1020</td><td valign="top"/></tr><tr><td valign="top">Commercial <break/>assay or kit</td><td valign="top">ABC kit</td><td valign="top">Vector Laboratories</td><td valign="top">Cat# Vector PK-6100 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2336819">AB_2336819</ext-link></td><td valign="top"/></tr><tr><td valign="top">Commercial <break/>assay or kit</td><td valign="top">BCA assay</td><td valign="top">Thermo Fisher</td><td valign="top">Cat# 23227</td><td valign="top"/></tr><tr><td valign="top">Commercial <break/>assay or kit</td><td valign="top">UltraView Universal DAB Detection Kit</td><td valign="top">Ventana Medical Systems</td><td valign="top">Cat# 760–500</td><td valign="top"/></tr><tr><td valign="top">Commercial <break/>assay or kit</td><td valign="top">VectaFluor Excel R.T.U. Antibody <break/>Kit, DyLight 488 Anti-Mouse</td><td valign="top">Vector Laboratories</td><td valign="top">Cat# DK-2488 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2336775">AB_2336775</ext-link></td><td valign="top"/></tr><tr><td valign="top">Chemical <break/>compound, <break/>drug</td><td valign="top">Doxycycline hyclate</td><td valign="top">Alfa Aesar</td><td valign="top">Cat# J60579</td><td valign="top">2 mg/ml</td></tr><tr><td valign="top">Chemical <break/>compound, <break/>drug</td><td valign="top">Sucrose</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# S0389</td><td valign="top">10 mg/ml</td></tr><tr><td valign="top">Chemical <break/>compound, <break/>drug</td><td valign="top">Tamoxifen</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# T5648</td><td valign="top">0.15 mg/g</td></tr><tr><td valign="top">Chemical <break/>compound, <break/>drug</td><td valign="top">Hoechst 33342</td><td valign="top">Life Technologies</td><td valign="top">Cat# H3570</td><td valign="top">1:10000</td></tr><tr><td valign="top">Chemical <break/>compound, <break/>drug</td><td valign="top">Laemmli buffer</td><td valign="top">Bio-Rad</td><td valign="top">Cat# 1704156</td><td valign="top"/></tr><tr><td valign="top">Chemical <break/>compound, <break/>drug</td><td valign="top">Clarity Western ECL Substrate</td><td valign="top">Bio-Rad</td><td valign="top">Cat# 170–5060</td><td valign="top"/></tr><tr><td valign="top">Chemical <break/>compound, <break/>drug</td><td valign="top">Alcian Blue</td><td valign="top">Alfa Aeser</td><td valign="top">Cat# J60122</td><td valign="top">1%</td></tr><tr><td valign="top">Chemical <break/>compound, <break/>drug</td><td valign="top">Acetic acid</td><td valign="top">VWR</td><td valign="top">Cat# 20103</td><td valign="top">3%</td></tr><tr><td valign="top">Chemical <break/>compound, <break/>drug</td><td valign="top">Periodic acid</td><td valign="top">VWR</td><td valign="top">Cat# 29460</td><td valign="top">1%</td></tr><tr><td valign="top">Chemical <break/>compound, <break/>drug</td><td valign="top">Schiff’s reagent</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# 88017</td><td valign="top"/></tr><tr><td valign="top">Software, <break/>algorithm</td><td valign="top">GraphPad Prism</td><td valign="top">GraphPad Software (<ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com">www.graphpad.com</ext-link>)</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_015807">SCR_015807</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, <break/>algorithm</td><td valign="top">Fiji</td><td valign="top"><xref ref-type="bibr" rid="bib47">Schindelin et al., 2012</xref> (Fiji.sc)</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002285">SCR_002285</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software, <break/>algorithm</td><td valign="top">ImageLab</td><td valign="top">BioRad</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">Probe: <italic>Ctgf</italic></td><td valign="top">ACDBio</td><td valign="top">Cat# 314541</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">Probe: <italic>Cyr61</italic></td><td valign="top">ACDBio</td><td valign="top">Cat# 429001</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">Probe: <italic>Lats2</italic></td><td valign="top">ACDBio</td><td valign="top">Cat# 420271</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">Probe: <italic>Nr5a1</italic></td><td valign="top">ACDBio</td><td valign="top">Cat# 445731</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">Probe: <italic>Tbx19</italic></td><td valign="top">ACDBio</td><td valign="top">Cat# 484741</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">Probe: <italic>Pou1f1</italic></td><td valign="top">ACDBio</td><td valign="top">Cat# 486441</td><td valign="top"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animals</title><p>Animal husbandry was carried out under compliance of the Animals (Scientific Procedures) Act 1986, Home Office license and KCL ethical review approval.</p><p>The <italic>Hesx1<sup>Cre/+</sup></italic> <xref ref-type="bibr" rid="bib2">Andoniadou et al., 2007</xref><italic>, Sox2<sup>CreERT2/+</sup></italic> <xref ref-type="bibr" rid="bib4">Andoniadou et al., 2013</xref>, <italic>Yap<sup>fl/fl</sup></italic> <sup>25</sup>, <italic>Taz<sup>-/-</sup></italic> <xref ref-type="bibr" rid="bib52">Tian et al., 2007</xref> (JAX:011120), <italic>R26<sup>mTmG/+</sup></italic> <xref ref-type="bibr" rid="bib34">Muzumdar et al., 2007</xref> (JAX:007576), <italic>ROSA26<sup>rtTA/+</sup></italic> <xref ref-type="bibr" rid="bib56">Yu et al., 2005</xref> (JAX:016999), <italic>Col1a1<sup>tetO-Yap/+</sup></italic> <xref ref-type="bibr" rid="bib20">Jansson and Larsson, 2012</xref> (MGI:5430522), <italic>Stk3<sup>fl/fl</sup>; Stk4<sup>fl/fl</sup></italic> <xref ref-type="bibr" rid="bib29">Lu et al., 2010</xref> (JAX:017635), and <italic>Lats1<sup>fl/fl</sup></italic> <xref ref-type="bibr" rid="bib16">Heallen et al., 2011</xref> (JAX:024941) and <italic>Lats2<sup>fl/fl</sup></italic> <xref ref-type="bibr" rid="bib16">Heallen et al., 2011</xref> (JAX:025428) have been previously described.</p><p>Tamoxifen (Sigma, T5648) was administered to experimental mice by intraperitoneal injection at a single dose of 0.15 mg/g body weight, or two equal doses on sequential days, depending on the experiment. Mice for growth studies were weighed every week. For embryonic studies, timed matings were set up where noon of the day of vaginal plug was designated as 0.5dpc.</p><p>For YAP-TetO experiments, crosses between <italic>Hesx1<sup>Cre/+</sup>;R26<sup>+/+</sup>;Col1a1<sup>+/+</sup></italic> and <italic>Hesx1<sup>+/+</sup>;R26<sup>rtTA/rtTA</sup>;Col1a1<sup>tetO-Yap/ tetO-Yap</sup></italic> animals were set up to generate <italic>Hesx1<sup>Cre/+</sup>;R26<sup>rtTA/+</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> offspring (hereby YAP-TetO) and control littermates, or crosses between <italic>Sox2<sup>CreERT2/+</sup>;R26<sup>mTmG/mTmG</sup>;Col1a1<sup>+/+</sup></italic> and <italic>Sox2<sup>+/+</sup>; R26<sup>rtTA/rtTA</sup>;Col1a1<sup>tetO-Yap/ tetO-Yap</sup></italic> animals were set up to generate <italic>Sox2<sup>CreERT2/+</sup>;R26<sup>rtTA/mTmG</sup>;Col1a1<sup>tetO-Yap/+</sup></italic> offspring. While treated with the tetracycline analogue doxycycline, YAP-TetO expressed rtTA from the <italic>ROSA26</italic> locus in <italic>Cre</italic>-derived cells, enabling YAP-S127A expression from the <italic>Col1a1</italic> locus. For embryonic studies between 5.5dpc and 15.5dpc (scheme, <xref ref-type="fig" rid="fig1">Figure 1A</xref>), doxycycline (Alfa Aesar, J60579) was administered to pregnant dams in the drinking water at 2 mg/ml, supplemented with 10% sucrose. For postnatal analyses animals were treated with doxycycline or vehicle (DMSO) as described, from the ages specified for individual experiments on the <italic>Hesx1<sup>Cre/+</sup></italic> driver, or directly following tamoxifen administration for animals on the <italic>Sox2<sup>CreERT2/+</sup></italic> driver. Both male and female mice and embryos where included in the studies.</p></sec><sec id="s4-2"><title>Tissue preparation</title><p>Embryos and adult pituitaries were fixed in 10% neutral buffered formalin (Sigma) overnight at room temperature. The next day, tissue was washed then dehydrated through graded ethanol series and paraffin-embedded. Embryos up to 13.5dpc were sectioned sagittal and all older embryo and postnatal samples were sectioned frontal, at a thickness of 7 µm for immunofluorescence staining, or 4 µm for RNAscope mRNA in situ hybridisation.</p></sec><sec id="s4-3"><title>RNAscope mRNA in situ hybridisation</title><p>Sections were selected for the appropriate axial level, to include Rathke’s pouch or pituitary, as described previously (<xref ref-type="bibr" rid="bib28">Lodge et al., 2016</xref>). The RNAscope 2.5 HD Reagent Kit-RED assay (Advanced Cell Diagnostics) was used with specific probes: <italic>Ctgf, Cyr61, Lats2</italic> (all ACDBio).</p></sec><sec id="s4-4"><title>H and E staining</title><p>Sections were dewaxed in histoclear and rehydrated through graded ethanol series from 100% to 25% ethanol, then washed in distilled H<sub>2</sub>O. Sections were stained with Haematoxylin QS (Vector #H3404) for 1 min, and then washed in water. Slides were then stained in eosin in 70% ethanol for 2 min and washed in water. Slides were dried and coverslips were mounted with VectaMount permanent mounting medium (Vector Laboratories H5000).</p></sec><sec id="s4-5"><title>Immunofluorescence and immunohistochemistry</title><p>Slides were deparaffinised in histoclear and rehydrated through a descending graded ethanol series. Antigen retrieval was performed in citrate retrieval buffer pH6.0, using a Decloaking Chamber NXGEN (Menarini Diagnostics) at 110°C for 3mins. Tyramide Signal Amplification (TSA) was used for staining using antibodies against YAP (1:1000, Cell Signaling #4912S), pYAP (1:1000, Cell Signaling #4911S), TAZ (1:1000, Atlas Antibodies #HPA007415) and SOX2 (1:2000, Abcam ab97959) with EMCN (1:1000, Abcam ab106100) staining as follows: sections were blocked in TNB (0.1M Tris-HCl, pH7.5, 0.15M NaCl, 0.5% Blocking Reagent (Perkin Elmer FP1020)) for 1 hr at room temperature, followed by incubation with primary antibody at 4°C overnight, made up in TNB. Slides were washed three times in TNT (0.1MTris-HCl pH7.5, 0.15M NaCl, 0.05% Tween-20) then incubated with secondary antibodies (biotinylated anti-rabbit (1:350 Abcam ab6720) and anti-Rat Alexa Fluor 555 (1:300, Life Technologies A21434) for 1 hr at room temperature and Hoechst (1:10000, Life Technologies H3570). Slides were washed again then incubated in ABC reagent (ABC kit, Vector Laboratories PK-6100) for 30 mins, followed by incubation with TSA conjugated fluorophore (Perkin Elmer NEL753001KT) for ten minutes. Slides were washed and mounted with VectaMount (Vector Laboratories H1000).</p><p>For regular immunofluorescence, sections were blocked in blocking buffer (0.15% glycine, 2 mg/ml BSA, 0.1% Triton-X in PBS), with 10% sheep serum (donkey serum for goat SOX2 antibody) for 1 hr at room temperature, followed by incubation with primary antibody at 4°C overnight, made up in blocking buffer with 1% serum. Primary antibodies used were against SOX2 (1:250, Immune Systems Ltd GT15098), active YAP (1:300, Abcam ab205270), GFP (1:300, Abcam ab13970), Ki-67 (1:300, Abcam ab16667), SOX9 (1:300, Abcam ab185230), PIT1 (1:1000, Gift from S. Rhodes, Indiana University), TPIT (1:1000, Gift from J. Drouin, Montreal), SF1 (1:200, Life Technologies N1665), Gamma H2A.X (1:1000, Abcam ab2893), Vimentin (1:300, Cell Signaling #5741), Caspase (1:300, Cell Signaling #9661S). Slides were washed in PBST then incubated with secondary antibodies for 1 hr at room temperature. Appropriate secondary antibodies were incubated in blocking buffer for 1 hr at room temperature (biotinylated anti-rabbit (1:350, Abcam ab6720), biotinylated anti-mouse (1:350, Abcam ab6788), anti-chicken 488 (1:300, Life Technologies A11039), anti-goat 488 (1:300, Abcam ab150133). Slides were washed again using PBST and incubated with fluorophore-conjugated Streptavidin (1:500, Life Technologies S21381 or S11223) for 1 hr at room temperature, together with Hoechst (1:10000, Life Technologies H3570). Slides were washed in PBST and mounted with VectaMount (Vector Laboratories, H1000).</p><p>Immunohistochemistry for the remaining antigens were undertaken on a Ventana Benchmark Autostainer (Ventana Medical Systems) using the following primary antibodies and antigen retrieval: AE1/AE3 (1:100, Dako M351529), CC1 (36 min, Ventana Medical Systems 950–124); Chromogranin (1:400, Dako M086901), CC1 (36 min, Ventana Medical Systems 950–124); NCAM (1:15, Novocastra NCL-L-CD56-504), CC1 (64 min, Ventana Medical Systems 950–124); NSE (1:1000, Dako M087329), CC1 (36 min, Ventana Medical Systems 950–124); p63 (1:100, A. Menarini Diagnostics), CC1 (64 min, Ventana Medical Systems 950–124) and Synaptophysin (1:2, Dako M731529), CC2 (92 min, Ventana Medical Systems 950–124). Targets were detected and viewed using the ultraView Universal DAB Detection Kit (Ventana Medical Systems, 760–500) according to manufacturer’s instructions.</p></sec><sec id="s4-6"><title>Alcian blue with periodic Acid-Schiff staining (AB/PAS)</title><p>Following deparaffinisation and rehydration, sections were taken through distilled water then placed in Alcian Blue solution (1% Alcian Blue (Alfa Aeser J60122) in 3% acetic acid (VWR International 20103)) for 20 min. Sections were then placed in 1% periodic acid (VWR 29460) for 10 min, washed in distilled water and transferred to Schiff’s reagent (Thermo Fisher Scientific 88017) for 10 min, followed by washing in distilled water for 5 min. Sections were then routinely dried, cleared and mounted.</p></sec><sec id="s4-7"><title>Western blotting</title><p>Dissected anterior pituitaries were flash frozen in liquid nitrogen and stored at −80°C. Frozen pituitaries were each lysed in 30 µl of lysis buffer (5 mM Tris, 150 mM NaCl, 1% protease and phosphatase inhibitor (Abcam ab201119), 5 μM EDTA, 0.1% Triton-X, pH7.6) and sonicated at 40% power, twice for ten cycles of: two seconds on/two seconds off, using a Vibra-Cell Processor (Sonics). Protein concentration was determined using the Pierce BCA protein assay kit (Thermo #23227) and all samples were diluted to 4 mg/ml in Laemmli buffer (Biorad #161–0747). Proteins were denatured at 95°C for 5 min. Samples were run on a 10% Mini-PROTEAN TGX polyacrylamide gel (BioRad #4561033), then transferred using Trans-Blot Turbo transfer machine (BioRad) onto polyvinylidene difluoride membranes (BioRad #1704156). Membranes were blocked with 5% non-fat dairy milk (NFDM) in TBST (20 mM Tris, 150 mM NaCl, 0.1% Tween-20, pH7.6), cut, then incubated with primary antibodies overnight at 4°C as follows: anti-STK3/STK4 (1:5000, Bethyl Laboratories #A300-466A) or Cyclophilin B (1:1000, R and D Systems #MAB5410) in 5%NFDM. The next day, membranes were washed in TBST, incubated with secondary antibodies HRP-conjugated anti-Rabbit (1:2000, Cell Signaling #7074) or HRP-conjugated anti-Mouse (1:2000, Cell Signaling #7076) in 5% NFDM for 1 hr at room temperature. After washing in TBST, membranes were treated with Clarity Western ECL substrate (Biorad #170–5060) and bands visualised using the ChemiDoc Touch Imaging System (BioRad). Protein abundance was analysed using ImageLabs (BioRad).</p></sec><sec id="s4-8"><title>Imaging</title><p>Wholemount images were taken with a MZ10 F Stereomicroscope (Leica Microsystems), using a DFC3000 G camera (Leica Microsystems). For bright field images, stained slides were scanned with Nanozoomer-XR Digital slide scanner (Hamamatsu) and images processed using Nanozoomer Digital Pathology View. Fluorescent staining was imaged with a TCS SP5 confocal microscope (Leica Microsystems) and images processed using Fiji (<xref ref-type="bibr" rid="bib47">Schindelin et al., 2012</xref>).</p></sec><sec id="s4-9"><title>Quantifications and statistics</title><p>Cell counts were performed manually using Fiji cell counter plug-in; 5–10 fields were counted per sample, totalling over 1500 nuclei, across 3–7 pituitaries. Statistical analyses and graphs were generated in GraphPad Prism (GraphPad Software) and the following tests were performed to determine significance: Student’s <italic>t</italic>-tests between controls and mutants for <xref ref-type="fig" rid="fig1">Figures 1D</xref> and <xref ref-type="fig" rid="fig2">2D</xref>, <xref ref-type="fig" rid="fig1s2">Figure 2—figure supplement 2D and 2E</xref> (n = 3 of each genotype), <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> (n = 4 of each genotype) and <xref ref-type="fig" rid="fig5">Figure 5C</xref> (n = 4–5 of each genotype); unpaired <italic>t</italic>-test for <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref> (n = 3 per genotype) and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2F</xref> (n = 6 sections across two samples per genotype); two-tailed <italic>t</italic>-test for <xref ref-type="fig" rid="fig3">Figure 3C</xref> (n = 3 controls, seven mutants); two-way ANOVA with Sidak’s multiple-comparison test for <xref ref-type="fig" rid="fig5">Figure 5F</xref> (n = 4–5 of each genotype). For quantification of target expression by RNAscope mRNA in situ hybridisation (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>), the area of positive staining (red fluorescence) from 4 μm sections was determined from images using thresholding in Fiji, and quantified as a percentage of total pituitary area in the same image. For statistical testing, one-way ANOVAs with Tukey’s multiple comparisons were performed (n = 4 mutants per genotype). Error bars in graphs show ±standard error of the mean, unless otherwise indicated. Quantification of STK3/4 by western blot was carried out on two control (<italic>Stk3<sup>fl/fl</sup>;Stk4<sup>fl/fl</sup></italic>) and three mutant (<italic>Hesx1<sup>Cre/+</sup>;Stk3<sup>fl/fl</sup>; Stk4<sup>fl/fl</sup></italic>) samples. A Student’s t-test was carried out on normalised band intensities. Chi-squared tests were used to determine significant deviations of observed from expected genotypes presented as tables in <xref ref-type="supplementary-material" rid="supp1">Supplementary files 1</xref> and <xref ref-type="supplementary-material" rid="supp2">2</xref>.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>This study has been supported by grant MR/L016729/1 from the MRC and a Lister Institute Research Prize to CLA, by the Deutsche Forschungsgemeinschaft (DFG) within the CRC/Transregio 205/1 as well as GRK 2251 to CLA and SRB. EJL was supported by the King’s Bioscience Institute and the Guy’s and St Thomas' Charity Prize PhD Programme in Biomedical and Translational Science. JPR was supported by a Dianna Trebble Endowment Fund Dental Institute Studentship. We thank Prof. Jacques Drouin and Prof. Simon Rhodes for TPIT and PIT1 antibodies respectively, and the National Hormone and Peptide Program (Harbor–University of California, Los Angeles Medical Center) for providing some of the hormone antibodies used in this study. We thank Prof. Juan Pedro Martinez-Barbera, Dr Rocio Sancho and Dr Marika Charalambous for discussions and critical reading of the manuscript. The authors declare no conflict of interest.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Validation, Investigation, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Validation, Investigation</p></fn><fn fn-type="con" id="con3"><p>Validation, Investigation</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con5"><p>Resources, Investigation</p></fn><fn fn-type="con" id="con6"><p>Resources, Methodology, Generation of the Stk3-flox, Stk4-flox, Lats1-flox and Lats2-flox mouse strains</p></fn><fn fn-type="con" id="con7"><p>Resources, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con8"><p>Supervision, Funding acquisition, Writing—review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Supervision, Funding acquisition, Methodology, Writing—original draft, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in accordance to UK Home Office Regulations and experimental procedures were approved by the King's College Ethical Review Process.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><object-id pub-id-type="doi">10.7554/eLife.43996.016</object-id><label>Supplementary file 1.</label><caption><title>Table showing expected and observed frequency of genotypes from <italic>Hesx1<sup>Cre/+</sup>;Yap<sup>fl/fl</sup>;Taz<sup>+/- </sup></italic>x <italic>Yap<sup>fl/fl</sup>;Taz<sup>+/- </sup></italic>at embryonic 15.5dpc and postnatal day 0–2.</title><p>Embryonic: p=0.3471, Chi-square test (two tailed). Postnatal: p=0.0003 (***), Chi-square test (two tailed).</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-43996-supp1-v2.docx"/></supplementary-material><supplementary-material id="supp2"><object-id pub-id-type="doi">10.7554/eLife.43996.017</object-id><label>Supplementary file 2.</label><caption><title>Table showing expected and observed frequency of genotypes from <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/+</sup>;Lats2<sup>fl/+</sup></italic> x <italic>Lats1<sup>fl/fl</sup>;Lats2<sup>fl/fl</sup></italic> and <italic>Hesx1<sup>Cre/+</sup>;Lats1<sup>fl/+</sup>;Lats2<sup>fl/+</sup></italic> x <italic>Lats1<sup>fl/fl</sup>;Lats2<sup>fl/+</sup></italic> at embryonic 15.5dpc and postnatal day 0–2.</title><p>Embryonic: p&lt;0.0001 (****), Chi-square test (two tailed). Postnatal: p&lt;0.0001 (****), Chi-square test (two tailed).</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-43996-supp2-v2.docx"/></supplementary-material><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.43996.018</object-id><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-43996-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>According to UK research councils’ Common Principles on Data Policy, all data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname> <given-names>AA</given-names></name><name><surname>Mohamed</surname> <given-names>AD</given-names></name><name><surname>Gener</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Taboada</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>YAP and the hippo pathway in pediatric cancer</article-title><source>Molecular &amp; Cellular Oncology</source><volume>4</volume><elocation-id>e1295127</elocation-id><pub-id pub-id-type="doi">10.1080/23723556.2017.1295127</pub-id><pub-id pub-id-type="pmid">28616573</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andoniadou</surname> <given-names>CL</given-names></name><name><surname>Signore</surname> <given-names>M</given-names></name><name><surname>Sajedi</surname> <given-names>E</given-names></name><name><surname>Gaston-Massuet</surname> <given-names>C</given-names></name><name><surname>Kelberman</surname> <given-names>D</given-names></name><name><surname>Burns</surname> <given-names>AJ</given-names></name><name><surname>Itasaki</surname> <given-names>N</given-names></name><name><surname>Dattani</surname> <given-names>M</given-names></name><name><surname>Martinez-Barbera</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Lack of the murine homeobox gene Hesx1 leads to a posterior transformation of the anterior forebrain</article-title><source>Development</source><volume>134</volume><fpage>1499</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1242/dev.02829</pub-id><pub-id pub-id-type="pmid">17360769</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andoniadou</surname> <given-names>CL</given-names></name><name><surname>Gaston-Massuet</surname> <given-names>C</given-names></name><name><surname>Reddy</surname> <given-names>R</given-names></name><name><surname>Schneider</surname> <given-names>RP</given-names></name><name><surname>Blasco</surname> <given-names>MA</given-names></name><name><surname>Le Tissier</surname> <given-names>P</given-names></name><name><surname>Jacques</surname> <given-names>TS</given-names></name><name><surname>Pevny</surname> <given-names>LH</given-names></name><name><surname>Dattani</surname> <given-names>MT</given-names></name><name><surname>Martinez-Barbera</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma</article-title><source>Acta Neuropathologica</source><volume>124</volume><fpage>259</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1007/s00401-012-0957-9</pub-id><pub-id pub-id-type="pmid">22349813</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andoniadou</surname> <given-names>CL</given-names></name><name><surname>Matsushima</surname> <given-names>D</given-names></name><name><surname>Mousavy Gharavy</surname> <given-names>SN</given-names></name><name><surname>Signore</surname> <given-names>M</given-names></name><name><surname>Mackintosh</surname> <given-names>AI</given-names></name><name><surname>Schaeffer</surname> <given-names>M</given-names></name><name><surname>Gaston-Massuet</surname> <given-names>C</given-names></name><name><surname>Mollard</surname> <given-names>P</given-names></name><name><surname>Jacques</surname> <given-names>TS</given-names></name><name><surname>Le Tissier</surname> <given-names>P</given-names></name><name><surname>Dattani</surname> <given-names>MT</given-names></name><name><surname>Pevny</surname> <given-names>LH</given-names></name><name><surname>Martinez-Barbera</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Sox2(+) stem/progenitor cells in the adult mouse pituitary support organ homeostasis and have tumor-inducing potential</article-title><source>Cell Stem Cell</source><volume>13</volume><fpage>433</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2013.07.004</pub-id><pub-id pub-id-type="pmid">24094324</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basu-Roy</surname> <given-names>U</given-names></name><name><surname>Bayin</surname> <given-names>NS</given-names></name><name><surname>Rattanakorn</surname> <given-names>K</given-names></name><name><surname>Han</surname> <given-names>E</given-names></name><name><surname>Placantonakis</surname> <given-names>DG</given-names></name><name><surname>Mansukhani</surname> <given-names>A</given-names></name><name><surname>Basilico</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Sox2 antagonizes the hippo pathway to maintain stemness in cancer cells</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>6411</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms7411</pub-id><pub-id pub-id-type="pmid">25832504</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batchuluun</surname> <given-names>K</given-names></name><name><surname>Azuma</surname> <given-names>M</given-names></name><name><surname>Fujiwara</surname> <given-names>K</given-names></name><name><surname>Yashiro</surname> <given-names>T</given-names></name><name><surname>Kikuchi</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Notch signaling and maintenance of SOX2 expression in rat anterior pituitary cells</article-title><source>Acta Histochemica Et Cytochemica</source><volume>50</volume><fpage>63</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1267/ahc.17002</pub-id><pub-id pub-id-type="pmid">28522881</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bronstein</surname> <given-names>MD</given-names></name><name><surname>Paraiba</surname> <given-names>DB</given-names></name><name><surname>Jallad</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Management of pituitary tumors in pregnancy</article-title><source>Nature Reviews Endocrinology</source><volume>7</volume><fpage>301</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2011.38</pub-id><pub-id pub-id-type="pmid">21403665</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camargo</surname> <given-names>FD</given-names></name><name><surname>Gokhale</surname> <given-names>S</given-names></name><name><surname>Johnnidis</surname> <given-names>JB</given-names></name><name><surname>Fu</surname> <given-names>D</given-names></name><name><surname>Bell</surname> <given-names>GW</given-names></name><name><surname>Jaenisch</surname> <given-names>R</given-names></name><name><surname>Brummelkamp</surname> <given-names>TR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>YAP1 increases organ size and expands undifferentiated progenitor cells</article-title><source>Current Biology</source><volume>17</volume><fpage>2054</fpage><lpage>2060</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2007.10.039</pub-id><pub-id pub-id-type="pmid">17980593</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>C-F</given-names></name><name><surname>Yeh</surname> <given-names>S-H</given-names></name><name><surname>Chen</surname> <given-names>D-S</given-names></name><name><surname>Chen</surname> <given-names>P-J</given-names></name><name><surname>Jou</surname> <given-names>Y-S</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Molecular genetic evidence supporting a novel human hepatocellular carcinoma tumor suppressor locus at 13q12.11</article-title><source>Genes, Chromosomes and Cancer</source><volume>44</volume><fpage>320</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1002/gcc.20247</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname> <given-names>LY</given-names></name><name><surname>Rizzoti</surname> <given-names>K</given-names></name><name><surname>Lovell-Badge</surname> <given-names>R</given-names></name><name><surname>Le Tissier</surname> <given-names>PR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Pituitary phenotypes of mice lacking the notch signalling ligand delta-like 1 homologue</article-title><source>Journal of Neuroendocrinology</source><volume>25</volume><fpage>391</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1111/jne.12010</pub-id><pub-id pub-id-type="pmid">23279263</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daly</surname> <given-names>AF</given-names></name><name><surname>Rixhon</surname> <given-names>M</given-names></name><name><surname>Adam</surname> <given-names>C</given-names></name><name><surname>Dempegioti</surname> <given-names>A</given-names></name><name><surname>Tichomirowa</surname> <given-names>MA</given-names></name><name><surname>Beckers</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium</article-title><source>The Journal of Clinical Endocrinology &amp; Metabolism</source><volume>91</volume><fpage>4769</fpage><lpage>4775</lpage><pub-id pub-id-type="doi">10.1210/jc.2006-1668</pub-id><pub-id pub-id-type="pmid">16968795</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname> <given-names>J</given-names></name><name><surname>Feldmann</surname> <given-names>G</given-names></name><name><surname>Huang</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>N</given-names></name><name><surname>Comerford</surname> <given-names>SA</given-names></name><name><surname>Gayyed</surname> <given-names>MF</given-names></name><name><surname>Anders</surname> <given-names>RA</given-names></name><name><surname>Maitra</surname> <given-names>A</given-names></name><name><surname>Pan</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Elucidation of a universal size-control mechanism in <italic>Drosophila</italic> and mammals</article-title><source>Cell</source><volume>130</volume><fpage>1120</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.07.019</pub-id><pub-id pub-id-type="pmid">17889654</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaston-Massuet</surname> <given-names>C</given-names></name><name><surname>Andoniadou</surname> <given-names>CL</given-names></name><name><surname>Signore</surname> <given-names>M</given-names></name><name><surname>Sajedi</surname> <given-names>E</given-names></name><name><surname>Bird</surname> <given-names>S</given-names></name><name><surname>Turner</surname> <given-names>JM</given-names></name><name><surname>Martinez-Barbera</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Genetic interaction between the homeobox transcription factors HESX1 and SIX3 is required for normal pituitary development</article-title><source>Developmental Biology</source><volume>324</volume><fpage>322</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2008.08.008</pub-id><pub-id pub-id-type="pmid">18775421</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Meljem</surname> <given-names>JM</given-names></name><name><surname>Haston</surname> <given-names>S</given-names></name><name><surname>Carreno</surname> <given-names>G</given-names></name><name><surname>Apps</surname> <given-names>JR</given-names></name><name><surname>Pozzi</surname> <given-names>S</given-names></name><name><surname>Stache</surname> <given-names>C</given-names></name><name><surname>Kaushal</surname> <given-names>G</given-names></name><name><surname>Virasami</surname> <given-names>A</given-names></name><name><surname>Panousopoulos</surname> <given-names>L</given-names></name><name><surname>Mousavy-Gharavy</surname> <given-names>SN</given-names></name><name><surname>Guerrero</surname> <given-names>A</given-names></name><name><surname>Rashid</surname> <given-names>M</given-names></name><name><surname>Jani</surname> <given-names>N</given-names></name><name><surname>Goding</surname> <given-names>CR</given-names></name><name><surname>Jacques</surname> <given-names>TS</given-names></name><name><surname>Adams</surname> <given-names>DJ</given-names></name><name><surname>Gil</surname> <given-names>J</given-names></name><name><surname>Andoniadou</surname> <given-names>CL</given-names></name><name><surname>Martinez-Barbera</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>1819</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-01992-5</pub-id><pub-id pub-id-type="pmid">29180744</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname> <given-names>ZY</given-names></name><name><surname>Richer</surname> <given-names>W</given-names></name><name><surname>Fréneaux</surname> <given-names>P</given-names></name><name><surname>Chauvin</surname> <given-names>C</given-names></name><name><surname>Lucchesi</surname> <given-names>C</given-names></name><name><surname>Guillemot</surname> <given-names>D</given-names></name><name><surname>Grison</surname> <given-names>C</given-names></name><name><surname>Lequin</surname> <given-names>D</given-names></name><name><surname>Pierron</surname> <given-names>G</given-names></name><name><surname>Masliah-Planchon</surname> <given-names>J</given-names></name><name><surname>Nicolas</surname> <given-names>A</given-names></name><name><surname>Ranchère-Vince</surname> <given-names>D</given-names></name><name><surname>Varlet</surname> <given-names>P</given-names></name><name><surname>Puget</surname> <given-names>S</given-names></name><name><surname>Janoueix-Lerosey</surname> <given-names>I</given-names></name><name><surname>Ayrault</surname> <given-names>O</given-names></name><name><surname>Surdez</surname> <given-names>D</given-names></name><name><surname>Delattre</surname> <given-names>O</given-names></name><name><surname>Bourdeaut</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>10421</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms10421</pub-id><pub-id pub-id-type="pmid">26818002</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heallen</surname> <given-names>T</given-names></name><name><surname>Zhang</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Bonilla-Claudio</surname> <given-names>M</given-names></name><name><surname>Klysik</surname> <given-names>E</given-names></name><name><surname>Johnson</surname> <given-names>RL</given-names></name><name><surname>Martin</surname> <given-names>JF</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hippo pathway inhibits wnt signaling to restrain cardiomyocyte proliferation and heart size</article-title><source>Science</source><volume>332</volume><fpage>458</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1126/science.1199010</pub-id><pub-id pub-id-type="pmid">21512031</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heaney</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Management of aggressive pituitary adenomas and pituitary carcinomas</article-title><source>Journal of Neuro-Oncology</source><volume>117</volume><fpage>459</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1007/s11060-014-1413-6</pub-id><pub-id pub-id-type="pmid">24584748</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>JK</given-names></name><name><surname>Du</surname> <given-names>W</given-names></name><name><surname>Shelton</surname> <given-names>SJ</given-names></name><name><surname>Oldham</surname> <given-names>MC</given-names></name><name><surname>DiPersio</surname> <given-names>CM</given-names></name><name><surname>Klein</surname> <given-names>OD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>An FAK-YAP-mTOR signaling axis regulates stem Cell-Based tissue renewal in mice</article-title><source>Cell Stem Cell</source><volume>21</volume><elocation-id>e106</elocation-id><pub-id pub-id-type="doi">10.1016/j.stem.2017.03.023</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingraham</surname> <given-names>HA</given-names></name><name><surname>Lala</surname> <given-names>DS</given-names></name><name><surname>Ikeda</surname> <given-names>Y</given-names></name><name><surname>Luo</surname> <given-names>X</given-names></name><name><surname>Shen</surname> <given-names>WH</given-names></name><name><surname>Nachtigal</surname> <given-names>MW</given-names></name><name><surname>Abbud</surname> <given-names>R</given-names></name><name><surname>Nilson</surname> <given-names>JH</given-names></name><name><surname>Parker</surname> <given-names>KL</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>The nuclear receptor steroidogenic factor 1 acts at multiple levels of the reproductive axis</article-title><source>Genes &amp; Development</source><volume>8</volume><fpage>2302</fpage><lpage>2312</lpage><pub-id pub-id-type="doi">10.1101/gad.8.19.2302</pub-id><pub-id pub-id-type="pmid">7958897</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansson</surname> <given-names>L</given-names></name><name><surname>Larsson</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Normal hematopoietic stem cell function in mice with enforced expression of the hippo signaling effector YAP1</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e32013</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0032013</pub-id><pub-id pub-id-type="pmid">22363786</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lasolle</surname> <given-names>H</given-names></name><name><surname>Cortet</surname> <given-names>C</given-names></name><name><surname>Castinetti</surname> <given-names>F</given-names></name><name><surname>Cloix</surname> <given-names>L</given-names></name><name><surname>Caron</surname> <given-names>P</given-names></name><name><surname>Delemer</surname> <given-names>B</given-names></name><name><surname>Desailloud</surname> <given-names>R</given-names></name><name><surname>Jublanc</surname> <given-names>C</given-names></name><name><surname>Lebrun-Frenay</surname> <given-names>C</given-names></name><name><surname>Sadoul</surname> <given-names>JL</given-names></name><name><surname>Taillandier</surname> <given-names>L</given-names></name><name><surname>Batisse-Lignier</surname> <given-names>M</given-names></name><name><surname>Bonnet</surname> <given-names>F</given-names></name><name><surname>Bourcigaux</surname> <given-names>N</given-names></name><name><surname>Bresson</surname> <given-names>D</given-names></name><name><surname>Chabre</surname> <given-names>O</given-names></name><name><surname>Chanson</surname> <given-names>P</given-names></name><name><surname>Garcia</surname> <given-names>C</given-names></name><name><surname>Haissaguerre</surname> <given-names>M</given-names></name><name><surname>Reznik</surname> <given-names>Y</given-names></name><name><surname>Borot</surname> <given-names>S</given-names></name><name><surname>Villa</surname> <given-names>C</given-names></name><name><surname>Vasiljevic</surname> <given-names>A</given-names></name><name><surname>Gaillard</surname> <given-names>S</given-names></name><name><surname>Jouanneau</surname> <given-names>E</given-names></name><name><surname>Assié</surname> <given-names>G</given-names></name><name><surname>Raverot</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas</article-title><source>European Journal of Endocrinology</source><volume>176</volume><fpage>769</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1530/EJE-16-0979</pub-id><pub-id pub-id-type="pmid">28432119</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavado</surname> <given-names>A</given-names></name><name><surname>Park</surname> <given-names>JY</given-names></name><name><surname>Paré</surname> <given-names>J</given-names></name><name><surname>Finkelstein</surname> <given-names>D</given-names></name><name><surname>Pan</surname> <given-names>H</given-names></name><name><surname>Xu</surname> <given-names>B</given-names></name><name><surname>Fan</surname> <given-names>Y</given-names></name><name><surname>Kumar</surname> <given-names>RP</given-names></name><name><surname>Neale</surname> <given-names>G</given-names></name><name><surname>Kwak</surname> <given-names>YD</given-names></name><name><surname>McKinnon</surname> <given-names>PJ</given-names></name><name><surname>Johnson</surname> <given-names>RL</given-names></name><name><surname>Cao</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The hippo pathway prevents YAP/TAZ-Driven hypertranscription and controls neural progenitor number</article-title><source>Developmental Cell</source><volume>47</volume><fpage>576</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2018.09.021</pub-id><pub-id pub-id-type="pmid">30523785</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>JH</given-names></name><name><surname>Kavanagh</surname> <given-names>JJ</given-names></name><name><surname>Wildrick</surname> <given-names>DM</given-names></name><name><surname>Wharton</surname> <given-names>JT</given-names></name><name><surname>Blick</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Frequent loss of heterozygosity on chromosomes 6q, 11, and 17 in human ovarian carcinomas</article-title><source>Cancer Research</source><volume>50</volume><fpage>2724</fpage><lpage>2728</lpage><pub-id pub-id-type="pmid">2328498</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Physiological implications of pituitary trophic activity</article-title><source>Journal of Endocrinology</source><volume>174</volume><fpage>147</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1677/joe.0.1740147</pub-id><pub-id pub-id-type="pmid">12176654</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname> <given-names>AJ</given-names></name><name><surname>Cooper</surname> <given-names>PW</given-names></name><name><surname>Kassel</surname> <given-names>EE</given-names></name><name><surname>Schwartz</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Squamous cell carcinoma arising in a suprasellar epidermoid cyst. case report</article-title><source>Journal of Neurosurgery</source><volume>59</volume><fpage>538</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.3171/jns.1983.59.3.0538</pub-id><pub-id pub-id-type="pmid">6886769</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Crenshaw</surname> <given-names>EB</given-names></name><name><surname>Rawson</surname> <given-names>EJ</given-names></name><name><surname>Simmons</surname> <given-names>DM</given-names></name><name><surname>Swanson</surname> <given-names>LW</given-names></name><name><surname>Rosenfeld</surname> <given-names>MG</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1</article-title><source>Nature</source><volume>347</volume><fpage>528</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1038/347528a0</pub-id><pub-id pub-id-type="pmid">1977085</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>C</given-names></name><name><surname>Yao</surname> <given-names>E</given-names></name><name><surname>Chuang</surname> <given-names>PT</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A conserved MST1/2-YAP axis mediates hippo signaling during lung growth</article-title><source>Developmental Biology</source><volume>403</volume><fpage>101</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2015.04.014</pub-id><pub-id pub-id-type="pmid">25912685</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lodge</surname> <given-names>EJ</given-names></name><name><surname>Russell</surname> <given-names>JP</given-names></name><name><surname>Patist</surname> <given-names>AL</given-names></name><name><surname>Francis-West</surname> <given-names>P</given-names></name><name><surname>Andoniadou</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Expression analysis of the hippo cascade indicates a role in pituitary stem cell development</article-title><source>Frontiers in Physiology</source><volume>7</volume><elocation-id>114</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2016.00114</pub-id><pub-id pub-id-type="pmid">27065882</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Kim</surname> <given-names>SM</given-names></name><name><surname>Bossuyt</surname> <given-names>W</given-names></name><name><surname>Liu</surname> <given-names>P</given-names></name><name><surname>Qiu</surname> <given-names>Q</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Halder</surname> <given-names>G</given-names></name><name><surname>Finegold</surname> <given-names>MJ</given-names></name><name><surname>Lee</surname> <given-names>JS</given-names></name><name><surname>Johnson</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver</article-title><source>PNAS</source><volume>107</volume><fpage>1437</fpage><lpage>1442</lpage><pub-id pub-id-type="doi">10.1073/pnas.0911427107</pub-id><pub-id pub-id-type="pmid">20080689</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>L</given-names></name><name><surname>Finegold</surname> <given-names>MJ</given-names></name><name><surname>Johnson</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Hippo pathway coactivators yap and taz are required to coordinate mammalian liver regeneration</article-title><source>Experimental &amp; Molecular Medicine</source><volume>50</volume><elocation-id>e423</elocation-id><pub-id pub-id-type="doi">10.1038/emm.2017.205</pub-id><pub-id pub-id-type="pmid">29303509</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazurenko</surname> <given-names>N</given-names></name><name><surname>Attaleb</surname> <given-names>M</given-names></name><name><surname>Gritsko</surname> <given-names>T</given-names></name><name><surname>Semjonova</surname> <given-names>L</given-names></name><name><surname>Pavlova</surname> <given-names>L</given-names></name><name><surname>Sakharova</surname> <given-names>O</given-names></name><name><surname>Kisseljov</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>High resolution mapping of chromosome 6 deletions in cervical cancer</article-title><source>Oncology Reports</source><volume>6</volume><fpage>859</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.3892/or.6.4.859</pub-id><pub-id pub-id-type="pmid">10373671</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname> <given-names>Z</given-names></name><name><surname>Moroishi</surname> <given-names>T</given-names></name><name><surname>Guan</surname> <given-names>KL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mechanisms of hippo pathway regulation</article-title><source>Genes &amp; Development</source><volume>30</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1101/gad.274027.115</pub-id><pub-id pub-id-type="pmid">26728553</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moroishi</surname> <given-names>T</given-names></name><name><surname>Park</surname> <given-names>HW</given-names></name><name><surname>Qin</surname> <given-names>B</given-names></name><name><surname>Chen</surname> <given-names>Q</given-names></name><name><surname>Meng</surname> <given-names>Z</given-names></name><name><surname>Plouffe</surname> <given-names>SW</given-names></name><name><surname>Taniguchi</surname> <given-names>K</given-names></name><name><surname>Yu</surname> <given-names>FX</given-names></name><name><surname>Karin</surname> <given-names>M</given-names></name><name><surname>Pan</surname> <given-names>D</given-names></name><name><surname>Guan</surname> <given-names>KL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A YAP/TAZ-induced feedback mechanism regulates hippo pathway homeostasis</article-title><source>Genes &amp; Development</source><volume>29</volume><fpage>1271</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1101/gad.262816.115</pub-id><pub-id pub-id-type="pmid">26109050</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muzumdar</surname> <given-names>MD</given-names></name><name><surname>Tasic</surname> <given-names>B</given-names></name><name><surname>Miyamichi</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Luo</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A global double-fluorescent cre reporter mouse</article-title><source>Genesis</source><volume>45</volume><fpage>593</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1002/dvg.20335</pub-id><pub-id pub-id-type="pmid">17868096</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nantie</surname> <given-names>LB</given-names></name><name><surname>Himes</surname> <given-names>AD</given-names></name><name><surname>Getz</surname> <given-names>DR</given-names></name><name><surname>Raetzman</surname> <given-names>LT</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Notch signaling in postnatal pituitary expansion: proliferation, progenitors, and cell specification</article-title><source>Molecular Endocrinology</source><volume>28</volume><fpage>731</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1210/me.2013-1425</pub-id><pub-id pub-id-type="pmid">24673559</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nantie</surname> <given-names>LB</given-names></name><name><surname>Young</surname> <given-names>RE</given-names></name><name><surname>Paltzer</surname> <given-names>WG</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Johnson</surname> <given-names>RL</given-names></name><name><surname>Verheyden</surname> <given-names>JM</given-names></name><name><surname>Sun</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title><italic>Lats1/2</italic> inactivation reveals hippo function in alveolar type I cell differentiation during lung transition to air breathing</article-title><source>Development</source><volume>145</volume><elocation-id>dev163105</elocation-id><pub-id pub-id-type="doi">10.1242/dev.163105</pub-id><pub-id pub-id-type="pmid">30305289</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nolan</surname> <given-names>LA</given-names></name><name><surname>Kavanagh</surname> <given-names>E</given-names></name><name><surname>Lightman</surname> <given-names>SL</given-names></name><name><surname>Levy</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Anterior pituitary cell population control: basal cell turnover and the effects of adrenalectomy and dexamethasone treatment</article-title><source>Journal of Neuroendocrinology</source><volume>10</volume><fpage>207</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2826.1998.00191.x</pub-id><pub-id pub-id-type="pmid">9576609</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Neill</surname> <given-names>BT</given-names></name><name><surname>Segkos</surname> <given-names>K</given-names></name><name><surname>Kasper</surname> <given-names>EM</given-names></name><name><surname>Pallotta</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Non-metastatic squamous cell carcinoma within a Rathke's cleft cyst</article-title><source>Pituitary</source><volume>19</volume><fpage>105</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1007/s11102-015-0638-5</pub-id><pub-id pub-id-type="pmid">25715776</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panciera</surname> <given-names>T</given-names></name><name><surname>Azzolin</surname> <given-names>L</given-names></name><name><surname>Fujimura</surname> <given-names>A</given-names></name><name><surname>Di Biagio</surname> <given-names>D</given-names></name><name><surname>Frasson</surname> <given-names>C</given-names></name><name><surname>Bresolin</surname> <given-names>S</given-names></name><name><surname>Soligo</surname> <given-names>S</given-names></name><name><surname>Basso</surname> <given-names>G</given-names></name><name><surname>Bicciato</surname> <given-names>S</given-names></name><name><surname>Rosato</surname> <given-names>A</given-names></name><name><surname>Cordenonsi</surname> <given-names>M</given-names></name><name><surname>Piccolo</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Induction of expandable Tissue-Specific stem/Progenitor cells through transient expression of YAP/TAZ</article-title><source>Cell Stem Cell</source><volume>19</volume><fpage>725</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2016.08.009</pub-id><pub-id pub-id-type="pmid">27641305</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papaspyropoulos</surname> <given-names>A</given-names></name><name><surname>Bradley</surname> <given-names>L</given-names></name><name><surname>Thapa</surname> <given-names>A</given-names></name><name><surname>Leung</surname> <given-names>CY</given-names></name><name><surname>Toskas</surname> <given-names>K</given-names></name><name><surname>Koennig</surname> <given-names>D</given-names></name><name><surname>Pefani</surname> <given-names>DE</given-names></name><name><surname>Raso</surname> <given-names>C</given-names></name><name><surname>Grou</surname> <given-names>C</given-names></name><name><surname>Hamilton</surname> <given-names>G</given-names></name><name><surname>Vlahov</surname> <given-names>N</given-names></name><name><surname>Grawenda</surname> <given-names>A</given-names></name><name><surname>Haider</surname> <given-names>S</given-names></name><name><surname>Chauhan</surname> <given-names>J</given-names></name><name><surname>Buti</surname> <given-names>L</given-names></name><name><surname>Kanapin</surname> <given-names>A</given-names></name><name><surname>Lu</surname> <given-names>X</given-names></name><name><surname>Buffa</surname> <given-names>F</given-names></name><name><surname>Dianov</surname> <given-names>G</given-names></name><name><surname>von Kriegsheim</surname> <given-names>A</given-names></name><name><surname>Matallanas</surname> <given-names>D</given-names></name><name><surname>Samsonova</surname> <given-names>A</given-names></name><name><surname>Zernicka-Goetz</surname> <given-names>M</given-names></name><name><surname>O'Neill</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>RASSF1A uncouples wnt from hippo signalling and promotes YAP mediated differentiation via p73</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>424</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-02786-5</pub-id><pub-id pub-id-type="pmid">29382819</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pefani</surname> <given-names>DE</given-names></name><name><surname>Latusek</surname> <given-names>R</given-names></name><name><surname>Pires</surname> <given-names>I</given-names></name><name><surname>Grawenda</surname> <given-names>AM</given-names></name><name><surname>Yee</surname> <given-names>KS</given-names></name><name><surname>Hamilton</surname> <given-names>G</given-names></name><name><surname>van der Weyden</surname> <given-names>L</given-names></name><name><surname>Esashi</surname> <given-names>F</given-names></name><name><surname>Hammond</surname> <given-names>EM</given-names></name><name><surname>O'Neill</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>RASSF1A-LATS1 signalling stabilizes replication forks by restricting CDK2-mediated phosphorylation of BRCA2</article-title><source>Nature Cell Biology</source><volume>16</volume><fpage>962</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1038/ncb3035</pub-id><pub-id pub-id-type="pmid">25218637</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pernicone</surname> <given-names>PJ</given-names></name><name><surname>Scheithauer</surname> <given-names>BW</given-names></name><name><surname>Sebo</surname> <given-names>TJ</given-names></name><name><surname>Kovacs</surname> <given-names>KT</given-names></name><name><surname>Horvath</surname> <given-names>E</given-names></name><name><surname>Young</surname> <given-names>WF</given-names></name><name><surname>Lloyd</surname> <given-names>RV</given-names></name><name><surname>Davis</surname> <given-names>DH</given-names></name><name><surname>Guthrie</surname> <given-names>BL</given-names></name><name><surname>Schoene</surname> <given-names>WC</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Pituitary carcinoma: a clinicopathologic study of 15 cases</article-title><source>Cancer</source><volume>79</volume><fpage>804</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19970215)79:4&lt;804::AID-CNCR18&gt;3.0.CO;2-3</pub-id><pub-id pub-id-type="pmid">9024719</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pulichino</surname> <given-names>AM</given-names></name><name><surname>Vallette-Kasic</surname> <given-names>S</given-names></name><name><surname>Tsai</surname> <given-names>JP</given-names></name><name><surname>Couture</surname> <given-names>C</given-names></name><name><surname>Gauthier</surname> <given-names>Y</given-names></name><name><surname>Drouin</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Tpit determines alternate fates during pituitary cell differentiation</article-title><source>Genes &amp; Development</source><volume>17</volume><fpage>738</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1101/gad.1065703</pub-id><pub-id pub-id-type="pmid">12651892</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzoti</surname> <given-names>K</given-names></name><name><surname>Akiyama</surname> <given-names>H</given-names></name><name><surname>Lovell-Badge</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mobilized adult pituitary stem cells contribute to endocrine regeneration in response to physiological demand</article-title><source>Cell Stem Cell</source><volume>13</volume><fpage>419</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2013.07.006</pub-id><pub-id pub-id-type="pmid">24094323</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saeger</surname> <given-names>W</given-names></name><name><surname>Lüdecke</surname> <given-names>DK</given-names></name><name><surname>Buchfelder</surname> <given-names>M</given-names></name><name><surname>Fahlbusch</surname> <given-names>R</given-names></name><name><surname>Quabbe</surname> <given-names>HJ</given-names></name><name><surname>Petersenn</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Pathohistological classification of pituitary tumors: 10 years of experience with the german pituitary tumor registry</article-title><source>European Journal of Endocrinology</source><volume>156</volume><fpage>203</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1530/eje.1.02326</pub-id><pub-id pub-id-type="pmid">17287410</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sajedi</surname> <given-names>E</given-names></name><name><surname>Gaston-Massuet</surname> <given-names>C</given-names></name><name><surname>Signore</surname> <given-names>M</given-names></name><name><surname>Andoniadou</surname> <given-names>CL</given-names></name><name><surname>Kelberman</surname> <given-names>D</given-names></name><name><surname>Castro</surname> <given-names>S</given-names></name><name><surname>Etchevers</surname> <given-names>HC</given-names></name><name><surname>Gerrelli</surname> <given-names>D</given-names></name><name><surname>Dattani</surname> <given-names>MT</given-names></name><name><surname>Martinez-Barbera</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Analysis of mouse models carrying the I26T and R160C substitutions in the transcriptional repressor HESX1 as models for septo-optic dysplasia and hypopituitarism</article-title><source>Disease Models and Mechanisms</source><volume>1</volume><fpage>241</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1242/dmm.000711</pub-id><pub-id pub-id-type="pmid">19093031</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname> <given-names>J</given-names></name><name><surname>Arganda-Carreras</surname> <given-names>I</given-names></name><name><surname>Frise</surname> <given-names>E</given-names></name><name><surname>Kaynig</surname> <given-names>V</given-names></name><name><surname>Longair</surname> <given-names>M</given-names></name><name><surname>Pietzsch</surname> <given-names>T</given-names></name><name><surname>Preibisch</surname> <given-names>S</given-names></name><name><surname>Rueden</surname> <given-names>C</given-names></name><name><surname>Saalfeld</surname> <given-names>S</given-names></name><name><surname>Schmid</surname> <given-names>B</given-names></name><name><surname>Tinevez</surname> <given-names>JY</given-names></name><name><surname>White</surname> <given-names>DJ</given-names></name><name><surname>Hartenstein</surname> <given-names>V</given-names></name><name><surname>Eliceiri</surname> <given-names>K</given-names></name><name><surname>Tomancak</surname> <given-names>P</given-names></name><name><surname>Cardona</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlegelmilch</surname> <given-names>K</given-names></name><name><surname>Mohseni</surname> <given-names>M</given-names></name><name><surname>Kirak</surname> <given-names>O</given-names></name><name><surname>Pruszak</surname> <given-names>J</given-names></name><name><surname>Rodriguez</surname> <given-names>JR</given-names></name><name><surname>Zhou</surname> <given-names>D</given-names></name><name><surname>Kreger</surname> <given-names>BT</given-names></name><name><surname>Vasioukhin</surname> <given-names>V</given-names></name><name><surname>Avruch</surname> <given-names>J</given-names></name><name><surname>Brummelkamp</surname> <given-names>TR</given-names></name><name><surname>Camargo</surname> <given-names>FD</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Yap1 acts downstream of α-catenin to control epidermal proliferation</article-title><source>Cell</source><volume>144</volume><fpage>782</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.031</pub-id><pub-id pub-id-type="pmid">21376238</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheng</surname> <given-names>HZ</given-names></name><name><surname>Zhadanov</surname> <given-names>AB</given-names></name><name><surname>Mosinger</surname> <given-names>B</given-names></name><name><surname>Fujii</surname> <given-names>T</given-names></name><name><surname>Bertuzzi</surname> <given-names>S</given-names></name><name><surname>Grinberg</surname> <given-names>A</given-names></name><name><surname>Lee</surname> <given-names>EJ</given-names></name><name><surname>Huang</surname> <given-names>SP</given-names></name><name><surname>Mahon</surname> <given-names>KA</given-names></name><name><surname>Westphal</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Specification of pituitary cell lineages by the LIM homeobox gene Lhx3</article-title><source>Science</source><volume>272</volume><fpage>1004</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1126/science.272.5264.1004</pub-id><pub-id pub-id-type="pmid">8638120</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>St John</surname> <given-names>MA</given-names></name><name><surname>Tao</surname> <given-names>W</given-names></name><name><surname>Fei</surname> <given-names>X</given-names></name><name><surname>Fukumoto</surname> <given-names>R</given-names></name><name><surname>Carcangiu</surname> <given-names>ML</given-names></name><name><surname>Brownstein</surname> <given-names>DG</given-names></name><name><surname>Parlow</surname> <given-names>AF</given-names></name><name><surname>McGrath</surname> <given-names>J</given-names></name><name><surname>Xu</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction</article-title><source>Nature Genetics</source><volume>21</volume><fpage>182</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1038/5965</pub-id><pub-id pub-id-type="pmid">9988269</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theile</surname> <given-names>M</given-names></name><name><surname>Seitz</surname> <given-names>S</given-names></name><name><surname>Arnold</surname> <given-names>W</given-names></name><name><surname>Jandrig</surname> <given-names>B</given-names></name><name><surname>Frege</surname> <given-names>R</given-names></name><name><surname>Schlag</surname> <given-names>PM</given-names></name><name><surname>Haensch</surname> <given-names>W</given-names></name><name><surname>Guski</surname> <given-names>H</given-names></name><name><surname>Winzer</surname> <given-names>KJ</given-names></name><name><surname>Barrett</surname> <given-names>JC</given-names></name><name><surname>Scherneck</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>A defined chromosome 6q fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer</article-title><source>Oncogene</source><volume>13</volume><fpage>677</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">8761288</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname> <given-names>Y</given-names></name><name><surname>Kolb</surname> <given-names>R</given-names></name><name><surname>Hong</surname> <given-names>JH</given-names></name><name><surname>Carroll</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>You</surname> <given-names>J</given-names></name><name><surname>Bronson</surname> <given-names>R</given-names></name><name><surname>Yaffe</surname> <given-names>MB</given-names></name><name><surname>Zhou</surname> <given-names>J</given-names></name><name><surname>Benjamin</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>TAZ promotes PC2 degradation through a SCFbeta-Trcp E3 ligase complex</article-title><source>Molecular and Cellular Biology</source><volume>27</volume><fpage>6383</fpage><lpage>6395</lpage><pub-id pub-id-type="doi">10.1128/MCB.00254-07</pub-id><pub-id pub-id-type="pmid">17636028</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Totaro</surname> <given-names>A</given-names></name><name><surname>Castellan</surname> <given-names>M</given-names></name><name><surname>Battilana</surname> <given-names>G</given-names></name><name><surname>Zanconato</surname> <given-names>F</given-names></name><name><surname>Azzolin</surname> <given-names>L</given-names></name><name><surname>Giulitti</surname> <given-names>S</given-names></name><name><surname>Cordenonsi</surname> <given-names>M</given-names></name><name><surname>Piccolo</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>YAP/TAZ link cell mechanics to notch signalling to control epidermal stem cell fate</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>15206</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms15206</pub-id><pub-id pub-id-type="pmid">28513598</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veldhuis</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Changes in pituitary function with ageing and implications for patient care</article-title><source>Nature Reviews Endocrinology</source><volume>9</volume><fpage>205</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2013.38</pub-id><pub-id pub-id-type="pmid">23438832</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xekouki</surname> <given-names>P</given-names></name><name><surname>Lodge</surname> <given-names>EJ</given-names></name><name><surname>Matschke</surname> <given-names>J</given-names></name><name><surname>Santambrogio</surname> <given-names>A</given-names></name><name><surname>Apps</surname> <given-names>JR</given-names></name><name><surname>Sharif</surname> <given-names>A</given-names></name><name><surname>Jacques</surname> <given-names>TS</given-names></name><name><surname>Aylwin</surname> <given-names>S</given-names></name><name><surname>Prevot</surname> <given-names>V</given-names></name><name><surname>Li</surname> <given-names>R</given-names></name><name><surname>Flitsch</surname> <given-names>J</given-names></name><name><surname>Bornstein</surname> <given-names>SR</given-names></name><name><surname>Theodoropoulou</surname> <given-names>M</given-names></name><name><surname>Andoniadou</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Non-secreting pituitary tumours characterised by enhanced expression of YAP/TAZ</article-title><source>Endocrine-Related Cancer</source><volume>26</volume><fpage>215</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1530/ERC-18-0330</pub-id><pub-id pub-id-type="pmid">30139767</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>HM</given-names></name><name><surname>Liu</surname> <given-names>B</given-names></name><name><surname>Chiu</surname> <given-names>SY</given-names></name><name><surname>Costantini</surname> <given-names>F</given-names></name><name><surname>Hsu</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Development of a unique system for spatiotemporal and lineage-specific gene expression in mice</article-title><source>PNAS</source><volume>102</volume><fpage>8615</fpage><lpage>8620</lpage><pub-id pub-id-type="doi">10.1073/pnas.0500124102</pub-id><pub-id pub-id-type="pmid">15941831</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Liu</surname> <given-names>CY</given-names></name><name><surname>Zha</surname> <given-names>ZY</given-names></name><name><surname>Zhao</surname> <given-names>B</given-names></name><name><surname>Yao</surname> <given-names>J</given-names></name><name><surname>Zhao</surname> <given-names>S</given-names></name><name><surname>Xiong</surname> <given-names>Y</given-names></name><name><surname>Lei</surname> <given-names>QY</given-names></name><name><surname>Guan</surname> <given-names>KL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition</article-title><source>Journal of Biological Chemistry</source><volume>284</volume><fpage>13355</fpage><lpage>13362</lpage><pub-id pub-id-type="doi">10.1074/jbc.M900843200</pub-id><pub-id pub-id-type="pmid">19324877</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>B</given-names></name><name><surname>Ye</surname> <given-names>X</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Lin</surname> <given-names>JD</given-names></name><name><surname>Wang</surname> <given-names>CY</given-names></name><name><surname>Chinnaiyan</surname> <given-names>AM</given-names></name><name><surname>Lai</surname> <given-names>ZC</given-names></name><name><surname>Guan</surname> <given-names>KL</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>TEAD mediates YAP-dependent gene induction and growth control</article-title><source>Genes &amp; Development</source><volume>22</volume><fpage>1962</fpage><lpage>1971</lpage><pub-id pub-id-type="doi">10.1101/gad.1664408</pub-id><pub-id pub-id-type="pmid">18579750</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>D</given-names></name><name><surname>Conrad</surname> <given-names>C</given-names></name><name><surname>Xia</surname> <given-names>F</given-names></name><name><surname>Park</surname> <given-names>JS</given-names></name><name><surname>Payer</surname> <given-names>B</given-names></name><name><surname>Yin</surname> <given-names>Y</given-names></name><name><surname>Lauwers</surname> <given-names>GY</given-names></name><name><surname>Thasler</surname> <given-names>W</given-names></name><name><surname>Lee</surname> <given-names>JT</given-names></name><name><surname>Avruch</surname> <given-names>J</given-names></name><name><surname>Bardeesy</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene</article-title><source>Cancer Cell</source><volume>16</volume><fpage>425</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2009.09.026</pub-id><pub-id pub-id-type="pmid">19878874</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>D</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name><name><surname>Barry</surname> <given-names>E</given-names></name><name><surname>Yin</surname> <given-names>Y</given-names></name><name><surname>Lawrence</surname> <given-names>E</given-names></name><name><surname>Dawson</surname> <given-names>D</given-names></name><name><surname>Willis</surname> <given-names>JE</given-names></name><name><surname>Markowitz</surname> <given-names>SD</given-names></name><name><surname>Camargo</surname> <given-names>FD</given-names></name><name><surname>Avruch</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance</article-title><source>PNAS</source><volume>108</volume><fpage>E1312</fpage><lpage>E1320</lpage><pub-id pub-id-type="doi">10.1073/pnas.1110428108</pub-id><pub-id pub-id-type="pmid">22042863</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Huang</surname> <given-names>T</given-names></name><name><surname>Cheng</surname> <given-names>A</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Kang</surname> <given-names>W</given-names></name><name><surname>To</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The TEAD family and its oncogenic role in promoting tumorigenesis</article-title><source>International Journal of Molecular Sciences</source><volume>17</volume><elocation-id>138</elocation-id><pub-id pub-id-type="doi">10.3390/ijms17010138</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>X</given-names></name><name><surname>Tollkuhn</surname> <given-names>J</given-names></name><name><surname>Taylor</surname> <given-names>H</given-names></name><name><surname>Rosenfeld</surname> <given-names>MG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Notch-Dependent pituitary SOX2(+) Stem cells exhibit a timed functional extinction in regulation of the postnatal gland</article-title><source>Stem Cell Reports</source><volume>5</volume><fpage>1196</fpage><lpage>1209</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2015.11.001</pub-id><pub-id pub-id-type="pmid">26651607</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.43996.020</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Horsley</surname><given-names>Valerie</given-names></name><role>Reviewing Editor</role><aff><institution>Yale University</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Camper</surname><given-names>Sally A</given-names></name><role>Reviewer</role><aff><institution>University of Michigan</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Emmerson</surname><given-names>Elaine</given-names> </name><role>Reviewer</role><aff><institution>The University of Edinburgh</institution><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Homeostatic and tumourigenic activity of <italic>Sox2Sox2</italic><sup>+</sup> pituitary stem cells is controlled by the LATS/YAP/TAZ cascade&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Marianne Bronner as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Sally A Camper (Reviewer #1); Elaine Emmerson (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>This paper assesses the roles of key candidates of the hippo pathway (MST, LATS, YAP, and TAZ) in pituitary stem cells (marked by <italic>SOX2</italic>). elegant loss-of-function and gain-of-function in vivo transgenic models coupled with immunofluorescence and high-powered microscopy to demonstrate that deletion of LATS kinases and subsequent upregulation of YAP/TAZ leads to a loss of regulation of SOX2+stem cells and uncontrolled expansion, ultimately leading to the formation of pituitary tumours. This well-written and nicely presented manuscript thoroughly examines the role of the hippo pathway in pituitary development and tumorigenesis. This work will broadly appeal to multiple fields including cancer and stem cell biology and could have significance in understanding the etiology of pediatric pituitary tumors.</p><p>Essential revisions:</p><p>1) Subsection “LATS, but not MST, kinases are required for normal pituitary development and differentiation”, second paragraph. Since the elimination of <italic>Mst1</italic> and <italic>Mst2</italic> did not produce any phenotype, it is important to demonstrate that the expression of these genes was actually knocked out. The <italic>Hesx1<sup>cre</sup></italic>strain is reliable and well-characterized, but there are examples of genes that are resistant to being knocked out for unknown reasons. Can you show by PCR or some other method that the genes were knocked out? It is worthwhile adding some discussion about Mst.</p><p>2) Quantification of much of the imaging data would strengthen the manuscript.</p><p>Could the authors graphically show the cell quantification data for PIT1, TPIT and SF1 in Figure 1, rather than stating it in the text, as this way the differences and significance would be much easier for the reader to appreciate? Similarly, for Figure 2B; Ki-67, SOX9, Figure 2D; PIT1, TPIT and SF1, Figure 4D; PIT1, TPIT and SF1, and Figure 5I; PIT1/GFP, SF1/GFP and ACTH/GFP.</p><p>Did the authors quantify the number of cells expressing SOX2 and active YAP in Figure 1—figure supplement 1D? From the images presented it appears that the number of cells expressing active YAP is reduced in the <italic>Hesx1<sup>Cre/+</sup>; Yap<sup>fl/fl</sup>; Taz</italic><sup>-/-</sup> mutants, so quantification would be advantageous.</p><p>The authors state an overgrowth of the RP in <italic>Hesx1<sup>Cre/+</sup>; Lats1<sup>fl/fl</sup>; Lats2<sup>fl/fl</sup></italic> mutants, could they measure and quantify the RP area and present this graphically?</p><p>3) It is not totally convincing that the phenotypic difference of postnatal <italic>Lats1/2</italic> removal (Figure 4) and YAP activation (Figure 5) is due to their intrinsic oncogenic potentials as the authors claim in Figure 6. It is possible that the inability of YAP to drive tumor formation from the Sox2+ stem cells is simply due to the levels of YAP transcriptional output between these two models. The authors should quantitatively measure the expression of YAP/TAZ target genes, such as CTGF, <italic>Cyr61</italic> and ANKRD1.</p><p>4) Are the controls displayed in Figure 3—figure supplement 14F normal tissue from wild-type littermate controls? Would the authors expect them to express markers of adenoma (Synaptophysin, NSE, Chromogranin) so strongly?</p><p>5) It is not clear why the authors restrict the analysis to embryonic stage in <italic>Hesx1<sup>CreER</sup>;R26<sup>rtTA</sup>;YAP<sup>teto</sup></italic> mice after Dox induction at e5.5. Are they embryonic lethal? If not, what are the postnatal phenotypes in these animals?</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.43996.021</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Subsection “LATS, but not MST, kinases are required for normal pituitary development and differentiation”, second paragraph. Since the elimination of Mst1 and Mst2 did not produce any phenotype, it is important to demonstrate that the expression of these genes was actually knocked out. The Hesx1<sup>cre</sup> strain is reliable and well-characterized, but there are examples of genes that are resistant to being knocked out for unknown reasons. Can you show by PCR or some other method that the genes were knocked out? It is worthwhile adding some discussion about Mst.</p></disp-quote><p>We agree that it is important to show deletion of <italic>Stk3</italic> and <italic>Stk4 (Mst2 and Mst1)</italic>. To this end we have carried out western blotting using an antibody recognising total STK3/4 proteins. This revealed over 75% overall decrease in STK3/4 protein in total anterior pituitary lysates from P35 <italic>Hesx1<sup>Cre/+</sup>;Stk3<sup>fl/fl</sup>; Hesx1<sup>Cre/+fl/fl</sup></italic> mutants compared with controls. The data and quantification are incorporated in Figure 2—figure supplement 1 and presented in the subsection “LATS, but not STK, kinases are required for normal pituitary development and differentiation”.</p><p>We have expanded discussion about STK in the second paragraph of the Discussion.</p><disp-quote content-type="editor-comment"><p>2) Quantification of much of the imaging data would strengthen the manuscript.</p><p>Could the authors graphically show the cell quantification data for PIT1, TPIT and SF1 in Figure 1, rather than stating it in the text, as this way the differences and significance would be much easier for the reader to appreciate? Similarly, for Figure 2B; Ki-67, SOX9, Figure 2D; PIT1, TPIT and SF1, Figure 4D; PIT1, TPIT and SF1, and Figure 5I; PIT1/GFP, SF1/GFP and ACTH/GFP.</p></disp-quote><p>We have quantified the data requested in Figures 1, 2, 4 and 5. These are now presented graphically in panels: Figure 1D (lineage markers), Figure 2D (lineage markers), Figure 5I (lineage/GFP), Figure 5—figure supplement 1A (lineage). Additional data, presented as new Figure 1—figure supplement 1B-G (embryonic YAP-TetO postnatal phenotype, see response to Point 5, below) and Figure 2—figure supplement 2F (Ki-67 and SOX9), have also been quantified and presented graphically.</p><disp-quote content-type="editor-comment"><p>Did the authors quantify the number of cells expressing SOX2 and active YAP in Figure 1—figure supplement 1D? From the images presented it appears that the number of cells expressing active YAP is reduced in the Hesx1<sup>Cre/+</sup>; Yap<sup>fl/fl</sup>; Taz<sup>-/-</sup> mutants, so quantification would be advantageous.</p></disp-quote><p>We agree with the reviewers that the number of SOX2+ cells expressing active YAP is reduced in these mutants and are keen to emphasise this point. We have quantified the cells expressing SOX2 and active YAP and present these in Figure 1—figure supplement 2D.</p><disp-quote content-type="editor-comment"><p>The authors state an overgrowth of the RP in Hesx1<sup>Cre/+</sup>; Lats1<sup>fl/fl</sup>; Lats2<sup>fl/fl</sup> mutants, could they measure and quantify the RP area and present this graphically?</p></disp-quote><p>As suggested, we have measured the area of the RP in these mutants and presented this graphically in Figure 2—figure supplement 2E.</p><disp-quote content-type="editor-comment"><p>3) It is not totally convincing that the phenotypic difference of postnatal Lats1/2 removal (Figure 4) and YAP activation (Figure 5) is due to their intrinsic oncogenic potentials as the authors claim in Figure 6. It is possible that the inability of YAP to drive tumor formation from the Sox2+ stem cells is simply due to the levels of YAP transcriptional output between these two models. The authors should quantitatively measure the expression of YAP/TAZ target genes, such as CTGF, Cyr61 and ANKRD1.</p></disp-quote><p>Unfortunately we have not been able to generate enough new samples to process for qRT from both of these mutants within the revision period. Therefore we have quantitated RNAscope assays across the tumour regions of several mutants of each genotype, facilitated by the auto-fluorescent properties of Fast Red used in this quantitative assay. As expected, the levels of YAP transcriptional output are lower in the YAP-TetO model compared to the LATS1/2 deletion in the <italic>Sox2CreERT2</italic> model. We have included a graph of the quantitation as Figure 5—figure supplement 1E and have included these findings in the Results.</p><p>Conceptually, we agree with the reviewers and did not mean to imply that tumours in the LATS1/2 deletion models are due to the intrinsic oncogenic potential of YAP/TAZ. In fact, we are fascinated by the possibility that the strength and duration of YAP/TAZ signaling are the only factors regulating a switch between normal stem cell expansion and tumourigenesis in this setting. Pragmatically, we interpret that results can be due to: (i) enhanced YAP/TAZ activity compared to the YAP-TetO model, as suggested; (ii) additional target expression unique to an increase in TAZ activation, not activated when YAP activity alone is enhanced; or, (iii) abnormal expression of additional, unidentified target proteins of LATS1 that might have oncogenic functions.</p><p>We have discussed the differences in levels of signaling between the models in the Discussion section. We have also amended the model in Figure 6 to highlight the difference in the levels of YAP/TAZ target activation.</p><disp-quote content-type="editor-comment"><p>4) Are the controls displayed in Figure 3—figure supplememt 1F normal tissue from wild-type littermate controls? Would the authors expect them to express markers of adenoma (Synaptophysin, NSE, Chromogranin) so strongly?</p></disp-quote><p>Indeed, the controls are from wild-type littermates. We do expect normal endocrine cells of the pituitary to express these neuroendocrine markers strongly (e.g. Stefaneanu L., et al. (1988) Arch Pathol Lab Med. PMID: 3134875; Van Noorden S., et al. (1984) Neuroendocrinology PMID: 6374489; Wilson B.S. and Lloyd R.V. (1984) Am J Pathol. PMID: 6375394). These markers are not diagnostic for pituitary tumour tissue, but are important for the classification of the tumour subtype, since they indicate the neuroendocrine nature of the tumour cells. All adenomas would be positive for Synaptophysin/NSE/Chromogranin, even null-cell adenomas that do not express lineage-commitment transcription factors. The negativity of the tissue is in line with the uncommitted/SOX2+ composition of the tumour, which is not undergoing neuroendocrine commitment as seen in the normal pituitary.</p><p>We have clarified that these three are neuroendocrine markers and not markers of adenomas, but that they stain pituitary adenomas, in the last paragraph of the subsection “Loss of LATS kinases results in carcinoma-like murine tumours” (Results).</p><disp-quote content-type="editor-comment"><p>5) It is not clear why the authors restrict the analysis to embryonic stage in Hesx1<sup>CreER</sup>;R26<sup>rtTA</sup>;YAP<sup>teto</sup> mice after Dox induction at e5.5. Are they embryonic lethal? If not, what are the postnatal phenotypes in these animals?</p></disp-quote><p>We particularly thank the reviewers for this suggestion, as it has revealed a novel phenotype.</p><p>Unfortunately with the induction at 5.5dpc, we could not recover any mutants after birth, and have now stated so in the text. However, we adapted the treatment to initiate doxycycline from 9.5dpc and obtained surviving mutants by P24 (4/5). The mutant animals had lower body weight and the anterior pituitary was smaller. Histological examination revealed a phenotype resembling Rathke’s cleft cyst, with multiple cysts developing across all mutant pituitaries. These most likely result from an expansion of SOX2+ cells that maintain epithelial integrity, and although we observe postnatal cell lineage commitment, this is impaired, resulting in in a decrease in PIT1+ cells.</p><p>Taking our embryonic and postnatal data together, we therefore conclude that a moderate increase in YAP/TAZ target expression maintains and promotes the SOX2+ fate, translating into deregulated lineage commitment and epithelial expansion with variable phenotypes depending on the timing, while a further elevation leads to the uncontrollable expansion and tumourigenesis. The new data are presented as new Figure1—figure supplement 1B-G, (Results subsection “Sustained conditional expression of YAP during development promotes SOX2+ PSC fate”) and (Discussion).</p></body></sub-article></article>